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Abstract 
 
Natural remedies from medicinal plants are considered to be effective and safe 
alternative treatment for diabetes mellitus. The aim of this study was to demonstrate 
the hypoglycaemic and antidiabetic activity of the aqueous extract of Icacina 
tracantha (tuber) (fam Icacinaceae)Ananas cosmos (fam. Bromeliaceae)and Uraria 
picta (leaves) (fam leguminosae) on an animal model of insulin resistance, a 
condition which predisposes to type 2 diabetes. The plants have a long history of use 
as anti-diabetic agents in western Nigeria. 
 
Method: 120 male Sprague-Dawley rats were assigned into two major groups. One 
group was fed on normal rat chow with the other group fed on a high calorie diet for 
four months a period sufficient for the animals to be fed to attain insulin resistance. 
The animals were then randomly assigned into different groups (each containing 6 
male rats). The plant crude extracts were made by weighing specific dried quantities 
of each plant, boiling in distilled water for about 2 hours, cooling overnight and 
separating solid from liquid by filtration. The solution was then poured into pre- 
weighed 250 ml beakers and allowed to dry in an oven at a temperature of 60oC. The 
dried, crude extracts were then weighed out and required doses prepared from the 
extracts. A non-treated group of animals was used as the control.  The mixed dose of 
extract was administered at 300 mg/kg. Over a 3 week period, all the animals were 
orally dosed with the different doses of plant extracts daily while metformin was 
administered through the animals’ drinking water, blood was collected from the tail 
vein of each rat prior to dosing and thereafter weekly, plasma was preserved and 
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analysed for glucose, insulin, free fatty acid concentrations and calculation of HOMA 
values to determine insulin sensitivity. During this period, the animals were weighed 
weekly and food intake was measured every three days. An oral glucose tolerance 
test (OGTT) was performed after the dosing period and fasting, 0, 30, 60 and 120 
minute blood samples were taken and assayed for glucose concentration. Animals 
were terminated and blood analysed. 
 
Statistical analysis: The results were tabulated as mean ± standard deviation and 
percentage median ± quartile range. The statistical analysis for other parameters was 
carried out via ANOVA (between groups) and Student’s paired T test (within groups). 
Only data from percentage median and quartile range was used because of the 
observed variation in glucose concentration between groups even at baseline values. 
Statistica software (StatSoft, Tulsa, OK, USA) was used for the analysis. 
 
Results: All plant extracts in the study showed differing concentration of significant 
difference in their effect on the plasma glucose, insulin and free fatty acid 
concentrations in the rat. The most significant effect was observed on the insulin 
concentration in the normal rat chow and high calorie diet fed animals. The plant 
extracts were observed to improve insulin sensitivity in most of the groups. This effect 
was more significant in the normal rat chow fed rats. The effect of the plant extracts 
on the weight, food consumed glucose and free fatty acid was minimal and in most of 
the groups was not significant. 
 
Conclusion: In conclusion, the results obtained suggest that the plant extracts may 
be used to improve insulin resistance in the management of diabetes mellitus.  
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CHAPTER 1. PREFACE. 
 
Evidence from fossil records date human use of plants as medicines at least to the 
Middle Paleolithic age some 60,000 years ago (Solecki and Shanidar, 1975). The 
earliest known medical document is a 4000-year-old Sumerian clay tablet that 
recorded plant remedies for various illnesses. The ancient Egyptian Ebers papyrus 
from 3500 year ago lists hundreds of remedies.  
 
 
Since ancient times, plant remedies have been used to help relieve diabetes. In the 
6th century B.C., Sushruta, an Indian physician classifying diabetes as a urinary 
disorder recommended plant remedies for its treatment and Gymnema sylvestre was 
advised for its treatment. (Shanmugasundaram et al, 2005). 
 
Medicinal plants are an important element of the indigenous medical systems in 
different parts of the world and plants have long provided mankind with a source of 
medicinal agents, with natural products once serving as the source of all drugs and in 
recent times as a major source of novel medicines in the pharmaceutical industry.  
(Ephraim et al, 2008). 
Different cultures have developed peculiar forms of traditional medical systems with 
medicinal plants for treating a number of diseases, including diabetes. In Ayurveda, 
Siddha and Unani systems of medicine, several herbs or plant products have been 
used for the treatment and management of diabetes mellitus (DM) (Raju et al, 2006). 
Though conventional synthetic drugs have made considerable progress in the 
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management of DM, traditional plant treatments for DM are also being used 
throughout the world and the search for natural anti-diabetic plant products for 
controlling DM is on-going. (Raju et al, 2006). 
 
Diabetes is a serious condition for the individual and society. Its rapidly increasing 
global prevalence is a significant cause for concern. The prevalence of diabetes 
throughout the world has increased dramatically over the recent past, and the trend 
will continue for the foreseeable future. One of the major concerns associated with 
diabetes relates to the development of micro- and macro-vascular complications, 
which contribute greatly to the morbidity and mortality associated with the disease. 
Progression of the disease from the pre-diabetic state to overt diabetes and the 
development of complications occur over many years (Cefalu, 2006). The prevalence 
of diabetes is higher in developed countries than in developing countries, but 
the latter will be hit the hardest by the escalating diabetes epidemic. Increased 
urbanization, westernization and economic development in developing countries have 
already contributed to a substantial rise in diabetes. The prevalence of diabetes in 
adults is projected to rise in both developed and developing countries.  While 
diabetes is most common among the elderly in many populations, prevalence rates 
are significantly rising among comparatively young and productive populations in the 
developing world (Website reference 1). 
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The total number of people with diabetes is projected to rise from 171 million in 2000 
to 366 million in 2030. These findings indicate that the “diabetes epidemic” will 
continue even if the prevalence of obesity remains constant. Given the increasing 
prevalence of obesity, it is likely that these figures provide an underestimate of future 
diabetes prevalence (Sarah et al, 2004). The epidemic nature of diabetes continues 
to affect ever-increasing numbers of people around the world while public awareness 
remains low. (Website reference 2). 
 
Various ethno-pharmacological surveys have shown that a number of medicinal 
plants have been used for the treatment of diabetes with various authors attesting to 
the efficacy of the plants in the control of both type 1 and II diabetes (Villasenor and 
Lamdrid, 2006; Maryna et al 2008). 
 
 
Although medicinal plants have been historically used for diabetes treatment 
throughout the world, few of them have been validated by scientific criteria (Medeiros 
et al, 2008). Numerous medicinal plants and herbal preparations have been shown to 
reduce blood glucose concentration through various mechanisms, although they are 
usually limited by toxicity or relative lack of efficacy compared with standard 
medications (Seham et al, 2006). 
 
The medicinal plants investigated in this study, icacina trichantha, ananas cosmos 
and uraria picta have been used in Western Nigeria for managing diabetes(personal 
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observation at Complete Cure HerbalClinic, 19 Igbobi College Road, Jibowu, Lagos)  
but without any scientific validation to confirm their anti-diabetic effects. 
 
 
The aim of this study wasto investigate the use of Icacina tricantha , Uraria picta and 
Ananas cosmos individually and in combination to lower blood glucose, insulin 
andfree fatty acid concentrations and improve insulin sensitivity in a rat model of 
insulin resistance. 
 
The study objectives included the following:  
 
• To determine the ability of the individual plant extracts to improve insulin 
sensitivity in Sprague Dawley (SD) male rats fed a high calorie or a normal rat chow 
diet. Insulin sensitivity will be determined by using the HOMA method: level of insulin 
resistance = [fasting insulin (μU/mL) × fasting glucose (mmol/L)]/22.5. 
• To determine the efficacy of the combination of the plant high calorie diet AC 
and Uraria picta extracts to improve insulin sensitivity in the animals.  
• To confirm the effect of the plant extracts on the biochemical parameters of 
insulin production, glucose lowering, and lowering of serum free fatty acid 
concentration. 
• To compare the anti-diabetic effect of the various plant extracts against a 
commonly used commercial therapy (metformin). 
A number of animal models have been employed to test and confirm the effect of 
medicinal plants on induced diabetes. In this research work, a rat animal model was 
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used.  The model was characterised by first feeding the animals on a high calorie diet 
for a period of four months to induce insulin resistance. 
 
The animals were then given the plant extracts orally for three weeks, weighed 
weekly, while blood samples were also collected weekly through the tail vein. An 
OGTT was performed after the period of three weeks following which the animals 
were terminated and blood samples collected. 
 
The OGTT is a diagnostic test that measures the body’s ability to metabolise glucose. 
It was performed to observe the effect of the plant extracts on glucose metabolism in 
the rats. Where the plants extracts had a positive effect on glucose metabolism the 
clearance rate was greater, and this is shown by measuring the area under the curve 
obtained from glucose readings taken over a 2 hour period. The plant extracts that 
have a better glucose clearance rate had a lower area under the glucose curve when 
compared to the control, untreated animals. 
 
Further analysis to ascertain the effect of the individual plant extracts, the 
combination of the extracts, metformin and non-treatment in all the groups of animals 
for the three week dosing period was carried out using weekly blood sample 
collected. The samples were analysed for glucose, insulin and free fatty acids. These 
are biochemical parameters that determine the effect of the plant extracts on 
diabetes.  
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The first chapter contains the introduction, background to study, prevalence of 
diabetes, aims and objectives of the study, methodology and rational of studies. This 
chapter describes the age long use of medicinal plant to treat different kinds of 
diseases, including diabetes. The chapter documents information showing the 
increasingly growing threat of diabetes, the possibility of finding alternative methods 
of treatment using medicinal plants, and the method to be employed in this study to 
achieve the aims listed.   
 
Chapter 2 defines the types and classification of diabetes mellitus and looks into the 
history of the disease from the time of its documented discovery, the economic 
burden associated with the disease, financial strains on nations and the association 
between diabetes and insulin resistance. The chapter further sheds more light on the 
growing influence of traditional medicine as a credible means of treating and 
managing diseases including diabetes. Furthermore, the chapter sheds more light on 
the rational for using the plants used in the present study, their history of use and 
literature review on these plants. 
 
The third chapter describes the materials, methods equipment and reagents used in 
the present study to investigate the possible anti diabetic effect of the medicinal 
plants using a rat model, based on feeding the animals on a HCD for four months. 
 
Chapter 4 is a composition of the results and data presented in tables and graphical 
figures. The chapter also describes the results obtained in the studies. 
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Chapter 5 contains the discussion on the outcome of the results obtained, the effects 
of the different medicinal plants on the biochemical parameters that affect diabetes 
including, plasma glucose concentration, weight of animals, food consumed, plasma 
insulin concentration, HOMA values, oral glucose test and FFA. 
 
Lastly, the 6th chapter documents the conclusion from the results obtained in the 
studies and inference drawn from the studies.    
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CHAPTER 2. DEFINITION, HISTORY, TYPES, 
CONSEQUENCES AND ECONOMIC BURDEN OF DIABETES 
 
2.1 Diabetes mellitus 
 
Diabetes mellitus (DM) is a condition primarily defined by the level of hyperglycemia 
giving rise to the risk of both micro- and macro-vascular damage. It is associated with 
reduced life expectancy, significant morbidity due to specific diabetes related 
microvascular complications (retinopathy, nephropathy and neuropathy), increased 
risk of macrovascular complications (ischaemic heart disease, stroke and peripheral 
vascular disease), and diminished quality of life. It is a metabolic disorder 
characterized by resistance to the action of insulin, insufficient insulin secretion, or 
both (Moore et al., 2004, WHO/IDF consultation, 2006).  
 
2.1.2 History of diabetes. 
 
The first observations of high glucose content in urine was made by early healers 
around 1500 BC while the first known recorded documentation of the disease was 
mentioned on a 3rd Dynasty Egyptian papyrus by the physician Hesy-Ra who 
mentions polyuria (frequent urination) as a symptom. 
 
Over the centuries, a number of early physicians have described the disease by its 
several symptoms.  Diabetes had no known cure or means of effectively treating 
diabetic patients until 1922 when experimental treatment with insulin was considered 
a success following the treatment of a 14 year old diabetic patient, by Dr. Banting, 
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Prof. Macleod and Dr .Collip, who were awarded a Noble prize in 1940. Further 
research led to the discovery of oral anti-diabetic agents in 1955. Over the years, the 
number of diabetic patients have been on a steady increase with the World Health 
Organization (WHO) estimating that about 300 million people will have the disease by 
the year 2030. (Website reference 3). 
 
2.1.3 Types of diabetes. 
 
The vast majority of diabetic patients are classified into one of two broad categories:  
 
Type 1 diabetes, also known as insulin-dependent diabetes which is caused by an 
absolute deficiency of insulin, Type 1 diabetes is characterized by a lack of insulin 
production. Without daily administration of insulin, Type 1 diabetes is fatal.  
Symptoms include excessive excretion of urine (polyuria), thirst (polydipsia), constant 
hunger, weight loss, vision changes and fatigue. These symptoms may occur 
suddenly. Type 1 diabetes is an autoimmune disease in which the insulin secreting -
cells of the pancreas are destroyed by the immune system.  
 
Type 2 diabetes, also known as non-insulin-dependent diabetes is characterized by 
the presence of insulin resistance with an inadequate compensatory increase in 
insulin secretion. Type 2 diabetes results from the body’s ineffective use of insulin. 
Type 2 diabetes comprises 90% of people with diabetes around the world, and is 
largely the result of excess body weight and physical inactivity.  Symptoms may be 
similar to those of Type 1 diabetes, but are often less marked. As a result, the 
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disease may be diagnosed several years after onset, once complications have 
already arisen. Until recently, this type of diabetes was seen only in adults but it is 
now also occurring in obese children (Weiss et al, 2004Pinkney, 2002). 
 
In addition, women who develop diabetes during their pregnancy are classified as 
having gestational diabetes. Symptoms of gestational diabetes are similar to Type 2 
diabetes. Gestational diabetes is most often diagnosed through prenatal screening, 
rather than reported symptoms and is associated with an increased risk of Type 2 
diabetes (Kim et al 2002). 
 
There are also a variety of uncommon and diverse types of diabetes which are 
caused by infections, drugs, endocrinopathies, pancreatic destruction, and genetic 
defects. These unrelated forms of diabetes are classified separately (WHO Fact 
sheet N°312, 2005, James et al, 2002, Website reference 4). 
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2.1.4 Consequences of diabetes 
 
In 2005, an estimated 1.1 million people died from diabetes. Almost 80% of diabetes 
deaths occur in low and middle-income countries. Almost half of diabetes deaths 
occur in people under the age of 70 years; 55% of diabetes deaths are in women. 
The WHO projects that diabetes deaths will increase by more than 50% in the next 
10 years without urgent action. Most notably, diabetes deaths are projected to 
increase by over 80% in upper-middle income countries between 2006 and 2015. 
Over time, the hyperglycaemia associated with diabetes can lead to damage to the 
heart, blood vessels, eyes, kidneys, and nerves (Ahhassh et al, 1995).  
 
• Diabetic retinopathy is an important cause of blindness, and occurs as a result of 
long-term accumulated damage to the small blood vessels in the retina. After 15 
years of diabetes, approximately 2% of people become blind, and about 10% develop 
severe visual impairment (WHO Fact sheet N°312, 2005).  
• Diabetic neuropathy is damage to the nerves as a result of diabetes, and affects 
up to 50% of people with diabetes. Although many different problems can occur as a 
result of diabetic neuropathy, common symptoms are tingling, pain, numbness, or 
weakness in the feet and hands.Neuropathy in the feet increases the chance of foot 
ulcers and eventual limb amputation. (WHO Fact sheet N°312, 2005).  
• Diabetes is among the leading causes of kidney failure: 10-20% of people with 
diabetes die of kidney failure(WHO Fact sheet N°312, 2005).  
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• Diabetes increases the risk of heart disease and stroke: 50% of people with 
diabetes die of cardiovascular disease (primarily heart disease and stroke) (WHO 
Fact sheet N°312, 2005).  
2.1.5 The economic burden of diabetes 
 
Diabetes and its complications impose significant economic consequences on 
individuals, families, health systems and countries. WHO estimates that over the next 
10 years (2006-2015), China will lose $558 billion in national income due to heart 
disease, stroke and diabetes alone (WHO Fact sheet N°312, 2005). 
The American Diabetes Association (ADA) estimated that the national costs of 
diabetes in the USA for 2002 was $US 132 billion, increasing to $US 192 billion in 
2020 (WHO/IDF consultation, 2006). 
2.1.6 Insulin resistance, hyperinsulinaemia and Type 2 diabetes 
 
Insulin resistance is the condition in which there is reduced sensitivity to normal 
concentrations of insulin, thus resulting in a situation where normal amounts of insulin 
are inadequate to produce a normal insulin response from fat, muscle and liver cells 
(Akbarzadeh et al, 2007). Insulin resistance in fat cells results in hydrolysis of stored 
triglycerides due to the reduced ability of insulin to inhibit lipolysis, which elevates 
free fatty acids in the blood plasma. Insulin resistance in muscle reduces glucose 
uptake, whereas insulin resistance in liver reduces glucose conversion to glycogen 
and blunts the ability of insulin to inhibit gluconeogenesis, with these effects serving 
to elevate blood glucose.  
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Although the primary factors causing Type 2 diabetes are unknown, it is clear that 
insulin resistance plays a major role in its development. (Shulman, 2000; Felber and 
Golay, 1995). 
 
Evidence for this comes from the presence of insulin resistance 10 – 20 years before 
the onset of the disease, from studies demonstrating that insulin resistance is a 
consistent finding in patients with Type 2 diabetes and, studies demonstrating that 
insulin resistance is the best predictor of whether or not an individual will become 
diabetic or not (Warram et al, 1990).  
 
This state described as “insulin resistant syndrome, metabolic syndrome or syndrome 
X” is characterized by abnormalities in glucose and lipid metabolism, obesity, high 
blood pressure and Type 2 diabetes. The causes of metabolic syndrome are 
extremely complex and have only been partially elucidated. However, metabolic 
syndrome is a progressive disorder, with a major outcome being Type 2 diabetes. 
Interventions that slow the rate of progression commonly reduce insulin resistance, 
supporting the importance of this parameter in disease progression. (Shulman, 2000). 
 
2.1.7. The aetiology of obesity-induced insulin resistance. 
 
Obesity is a major cause of type 2 diabetes (T2DM) in all affected populations, 
however, obesity is neither sufficient nor necessary to develop T2DM or cause insulin 
resistance (Tataranni, 2002). Even though the exact aetiology of obesity is not 
known, it is widely accepted that the disease is caused by an imbalance of energy 
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intake and expenditure in the body, where more energy is taken in and stored than is 
expended.(Roberts et al, 2004). Adipose tissue or body fat or just fat is loose 
connective tissue composed of adipocytes. It is technically composed of roughly only 
80% fat. Obesity dose not just set in when there is excess weight but it is best 
considered as being an increase in adiposity involving an increase in adipose tissue 
mass. (Coppack, 2005) 
 
Adipose tissue is not just a collection of fat with the role of insulating and protecting 
the body. It has been established that adipose tissue is an endocrine organ involved 
in secreting a number of bioactive peptides and factors. These factors and peptides 
include leptin, angiotensinogen, cytokines, adiponectin,complement components, 
plasminogen activator inhibitor-1, proteins of the renin-angiotensin system, and 
resistin.(Kershaw et al, 2004, Ahima et al, 2006).  
 
The important endocrine function of adipose tissue is emphasized by the adverse 
metabolic consequences of both adipose tissue excess and deficiency. Cytokines like 
TNF alpha and interleukin 6 (IL-6) have been implicated in the pathogenesis of 
obesity and insulin resistance. Adipose tissue expression of TNF is elevated in obese 
rodents and humans and is positively correlated with obesity and insulin resistance 
(Lorenzo et al, 2007, Ruan et al, 2003) 
 
 In rodents, resistin can induce insulin resistance. Adipose tissue IL-6 expression and 
circulating IL-6 concentrations are positively correlated with obesity, impaired glucose 
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tolerance, and insulin resistance. Furthermore, plasma IL-6 concentrations predict the 
development of type 2 diabetes and cardiovascular disease. Peripheral 
administration of IL-6i nduces hyperlipidemia, hyperglycemia, and insulin resistance 
in rodents and humans. IL-6 also decreases insulin signalling in peripheral tissues by 
reducing expression of insulin receptor signalling components. IL-6 also inhibits 
adipogenesis and decreases adiponectin secretion. (Tiziana et al, 2006) 
 
Adiponectin is highly expressed in adipose tissue, and circulating adiponectin 
concentration is decreased in subjects with obesity-related insulin resistance and 
type 2 diabetes. Adiponectin inhibits liver gluconeogenesis and promotes fatty acid 
oxidation in skeletal muscle. In addition, adiponectin counteracts the pro-
inflammatory effects of TNF-alpha on the arterial wall and probably protects against 
the development of arteriosclerosis (Bastard et al, 2006, Wassink et al, 2007). 
 
2.1.8. Visceral obesity intra-muscular fat deposition and insulin resistance. 
 
Regional fat distribution is a risk factor for the development of type II diabetes and 
insulin resistance. Obese individuals with high levels of visceral fat are at a higher risk of 
developing both type 2 diabetes and insulin resistance. (Després, 1993) 
 
Visceral obesity is a form of obesity due to excessive deposition of fat around the 
abdominal viscera, and is associated with dyslipidemia (increased plasma triglyceride, 
low high-density lipoprotein cholesterol) and poses a greater risk of diabetes mellitus, 
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insulin resistance, hypertension, metabolic syndrome, and cardiovascular disease than 
does peripheral obesity.(Busetto, 2001). Surgical removal of visceral fat leads to the 
improvement of insulin resistance in rodents (Barzilai et al. 1999). 
 
Obese subjects have high levels of ectopic intra-muscular fat deposition which 
correlates positively with visceral fat levels. (Hansen et al, 1997). It has been shown that 
intra-muscular fat deposition correlates strongly with whole body insulin resistance (Soo 
et al, 2008, Tisha and Steven, 2007 ), possibly by reducing skeletal muscle insulin 
receptor signalling (Melpomeni et al, 2007).Furthermore,  a moderate reduction in the 
triglyceride content of muscle via weight loss  was shown to improve insulin 
resistance.(Mazzali et al, 2006) 
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2.1.9 The challenge of treating diabetes 
 
Although the modern allopathic system of medicine is greatly accepted in the 
treatment of diabetes throughout the world, managing both Type 1 and Type 2 
diabetes remains a major challenge. The present mainstream drugs for treating the 
disease, though effective have a number of limitations and challenges to the 
administration of health care in diabetic patients, including side effects and primary 
and secondary drug failures (Kochhar and Malkit, 2005).   
Patients are known to experience both primary failure, where the patient does not 
respond to the initial medication for treatment and secondary drug failure where 
failure in treatment sets in after an initial response to the treatment. Secondary failure 
to oral hypoglycemic agents is defined as a good initial response to oral agents (at 
least one month) with decreasing effectiveness and eventual failure. In such cases, 
the drug therapy is changed or extra therapy is added. Ultimately, most Type 2 
diabetic patients will need exogenous insulin therapy (Knut, 1999). The incidence of 
secondary drug failure, as published in literature is 0.3% to 30% (Batra, 1991). 
 
In Type 2 diabetes, the successive failure of non-pharmacologic therapy and oral 
antihyperglycemic agents eventually burdens patients with a heavy history of 
uncontrolled hyperglycemia (Brown et al, 2004, Maru et al, 2005). 
 
The use of anti-diabetic drugs is a continuous process, and patients have to take 
these drugs daily. One alternative that has shown  some  promise in helping 
overcome some of these challenges are medicinal plants used individually or in 
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combination. Among the many diseases that have led to the increased use of 
medicinal plants is diabetes mellitus. Several herbs have been shown to be highly 
effective in controlling blood sugar concentration and reducing problems associated 
with diabetes. These herbs sometimes may act as a monotherapy and most of the 
time they can be taken in addition to other anti-diabetic drugs (Eddouks et al, 2002, 
Omar et al, 2008).  It is interesting to note that one of the most common drugs used 
for the treatment of Type 2 diabetes is metformin, the parent drug having been 
originally derived from the French lilac (Witters, 2001). 
 
2.2.0 Anti-diabetic drugs used for managing insulin resistance 
 
The challenges and economic threats posed by the disease highlighted above has 
necessitated continual research into potential new therapies for the treatment of 
diabetes and insulin resistance. Even though no known cure for diabetes has been 
discovered, a number of medications have been used to treat and manage the ailment 
successfully. 
 
Given the association between type 2 diabetes and insulin resistance, most of the 
classes of drugs used for the treatment of diabetes are potent insulin sensitising agents. 
These classes of drugs include the biguanides and the thiazolidinediones. 
 
Examples of thiazolidinediones include rosiglitazone and pioglitazone. While metformin 
is the most widely used biguanide.   Thiazolidinediones and biguanides counter insulin 
resistance, but act by different mechanisms. The two agents are able to lower blood 
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glucose concentrations in type 2 diabetes without occurring overt hypoglycemia and 
both require the presence of insulin to generate their therapeutic effects, but act without 
stimulating insulin secretion (Masuda and Terauchi, 2010). 
 
The two agents are also used in combination therapy to manage diabetes and insulin 
resistance. Metformin exerts a stronger suppression of hepatic glucose output, while 
thiazolidinediones produces a greater increase in peripheral glucose uptake, enabling 
metformin-thiazolidinedione combinations to improve glycaemic control in type 2 
diabetes with additive efficacy. Basal insulin concentrations are not raised by metformin 
or thiazolidinediones, so there is minimal risk of hypoglycaemia, and metformin can 
reduce the weight gain associated with thiazolidinediones (Bailey, 2005)  
 
Single pill combinations of rosiglitazone/metformin and pioglitazone/metformin have 
recently been approved for use in the US and Europe. (Masuda and Terauchi, 2010) 
 
Metformin has been shown to act via activating the intracellular kinase, AMP-activated 
protein kinase (AMPK) (Sirtori and Pasik, 1994). This enzyme is able to increase cellular 
glucose uptake and reduce hepatic gluconeogenesis. The thiazolidinediones act via 
binding to the transcription factor peroxisome proliferator-activated receptor (PPAR)-, 
which is highly expressed in adipocytes. This leads to increased adipogenesis and the 
production of small, insulin sensitive adipocytes, which may act as glucose “sinks” 
(Lessard et al, 2007). Activation of PPAR- also leads to increased adipocyte secretion 
of adiponectin and reduced secretion of TNF (Hannele, 2004).   
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2.2 Traditional medicine 
 
 
Traditional medicine (TM) is the sum total of the knowledge, skills, and practices 
based on the theories, beliefs, and experiences indigenous to different cultures, 
whether explicable or not, used in the maintenance of health as well as in the 
prevention, diagnosis, improvement or treatment of physical and mental illness. It 
also refers to health practices, approaches, knowledge and beliefs incorporating 
plant, animal and mineral based medicines, spiritual therapies, manual techniques 
and exercises, applied singularly or in combination to treat, diagnose and prevent 
illnesses or maintain well-being. (World Health Organization, Ernst et al, 1995). 
 
2.2.1 Increasing use and popularity of traditional medicine 
 
Traditional medicine has maintained its popularity in all regions of the developing 
world and its use is rapidly spreading in industrialized countries. 
• In China, traditional herbal preparations account for 30%-50% of the total 
medicinal consumption. (WHO, Fact sheet N°134, 2003). 
• In Ghana, Mali, Nigeria and Zambia, the first line of treatment for 60% of children 
with high fever resulting from malaria is the use of herbal medicines at home. (WHO, 
Fact sheet N°134, 2003). 
• World Health Organization estimates that in several African countries traditional 
birth attendants assist in the majority of births. (WHO, Fact sheet N°134, 2003). 
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• In Europe, North America and other industrialized regions, over 50% of the 
population have used complementary or alternative medicine at least once. (WHO, 
Fact sheet N°134, 2003). 
• In San Francisco, London and South Africa, 75% of people living with HIV/AIDS 
use TM.  
• 70% of the population in Canada has used complementary medicine at least 
once. (WHO, Fact sheet N°134, 2003). 
• In Germany, 90% of the population has used a natural remedy at some point in 
their life. Between 1995 and 2000, the number of doctors who had undergone special 
training in natural remedy medicine had almost doubled to 10 800. (WHO, Fact sheet 
N°134, 2003). 
• In the United States, 158 million of the adult population use complementary 
medicines and according to the USA Commission for Alternative and Complementary 
medicines, US $17 billion was spent on traditional remedies in 2000. (WHO, Fact 
sheet N°134, 2003). 
• In the United Kingdom, annual expenditure on alternative medicine is US$ 230 
million. (WHO, Fact sheet N°134, 2003). 
• The global market for herbal medicines currently stands at over US $ 60 billion 
annually and is growing steadily (WHO, Fact sheet N°134, 2003). 
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2.2.2 Tried and tested methods and products 
 
It has been estimated that 25% of modern medicines are made from plants first used 
traditionally (W.H.O.). Traditional medicine can have an impact on infectious 
diseases. For example, the Chinese herbal remedy Artemisia annua, used in China 
for almost 2000 years has been found to be effective against resistant malaria and 
could create a breakthrough in preventing almost one million deaths annually, most of 
them children, from severe malaria (WHO monograph on good agricultural and 
collection practices (GACP) for Artemisia annua L.) 
 
 In South Africa, the Medical Research Council is conducting studies on the efficacy 
of the plant Sutherlandia Microphylla in treating AIDS patients. Traditionally used as a 
tonic, this plant may increase energy, appetite and body mass in people living with 
HIV (WHO, Fact sheet N°134,2003). 
 
It is known that about seventy countries have a national regulation on herbal 
medicines but the legislative control of medicinal plants has not evolved around a 
structured model. This is because medicinal products or herbs are defined differently 
in different countries and diverse approaches have been adopted with regard to 
licensing, dispensing, manufacturing and trading (WHO, Fact sheet N°134, 2003). 
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2.2.3 Traditional medicine use in Africa 
 
The use of traditional herbal medicine on the African continent has continually been 
on the rise due to the following reasons: 
 
• It is cheaper than orthodox medicine in Africa, more accessible to the African 
villagers and is more acceptable to Africans than modern medicine.   
• Alternative and traditional medicine (ATM) is a potential source of new plant 
derived drugs, a source of cheap starting products for synthesis of known drugs, or a 
cheap source of known drugs such as reserpine, vinblastine, etc. 
• Alternative and traditional medicine remedies are mostly compounded from 
natural products (herbs); so they should be readily acceptable to the body. 
(Sofowora, 1996).  
• Traditional medicinal plants are presently used by over 70% of the world’s 
population according to the World Health Organization. This trend has continued to 
experience increased growth in patronage as they are considered to be safer with 
less toxicity, readily available, more affordable and accessible particularly to the 
indigenous populations of third world nations where medical plants remain the main 
form of health care treatment (Website reference 5). 
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2.3  Medicinal plants in diabetes research and treatment. 
 
Plants remain a major source of raw materials for medicines and drugs. Research is 
on going to discover novel anti-diabetic drug candidates from plants. Till date, about 
400 plant species have been identified and documented as medicinal plants with anti-
diabetic properties (Ajay et al, 2006). 
 
Presently, several research projects on anti-diabetic medicinal plants are at different 
stages of development. A good example is dianex, a poly herbal formulation 
consisting of the aqueous extracts of Gymnema sylvestrte, Eugenia jambolana, 
Mormordica charantia, Azadirachta indica, Cassia auriculata, Aegle marmelose, 
Withania somnifera andCurcuma longa,which was shown to produce significant 
hypoglycemic activity in both normal and diabetic mice while also reversing other 
diabetic complications. (Mutalik et al, 2005). 
 
Jia et al (2003) have documented the results of their research on seven commercially 
available Chinese polyherbal products with each polyherbal formulation producing 
significant dose-dependent blood glucose lowering activity in various animal models 
as well as in humans. 
 
Korean scientists working on a polyherbal formulation “SMK001” concluded that 
continuous treatment of rats made diabetic by the use of stretozotocin with SMK001 
produced a significant decrease in the blood and urine glucose concentration (Jong 
et al, 2006). 
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Also, household plants like ginger and garlic have been widely reported to positively 
impact and improve the state of diabetic subjects (Khaled et al, 2008). 
 
2.4 About the plants used in this study 
 
2.4.1 Icacina trichantha (Family,Icacinaceae) 
The plant is a shrub that arises from a stout hairy underground tube with a stem 
straggling with soft brown hairs. The flowers are cream, petals hairy with slightly hairy 
fruits up to 2.5 cm when ripe. This undergrowth is common in West Africa and 
Southern Nigeria.(Gbile et al, June 1993). 
 
Acute toxicity testing of aqueous extracts of the tuber in mice at a maximum 
administered dose of 1.6g/kg body weight resulted in 40% death. No death was 
observed at 800mg/kg body weight administered to the animals (Asuzu and 
Ugwueze, 1990). The tuber of icacina trichantha extracted with 50% methanol 
induced sleep in rats treated with doses ranging from 400 -1000 mg/kg body weight 
intraperitoneally (i.  p). The LD50 of the methanolic tuber extract in rats was 671mg/kg 
body weight, i p (Asuzu and Abubarkar, 1995). Moderate antioxidant property was 
reported by Oke and Hamburger, (2002). No analysis of the anti-diabetic properties of 
this plant has been conducted despite its traditional use in the treatment of diabetes. 
2.4.2 Uraria picta (Jacq.) DC. (Family,Leguminosae-papilionoideae) 
 
The plant is an herbaceous annual plant growing to between 0.5 – 1 meter in height. 
The stems are covered with short crooked hairs. Fruits are made of short pods with 4 
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to 5 articles twisted like an accordion. The plant is a paleotropical species, growing in 
all the African savannahs, south of the Sahara (Adjanohun et al, 1991). 
 
Ethno-medical uses of the plant, Uraria picta, in Nigeria include the treatment of skin 
diseases and for accelerating fracture wound healing. The plant extract is also used 
to control ecto-parasites in man and domestic animals. Methanolic and aqueous LC50 
of the plant were reported as 2,700 micrograms/ml and 57,000 micrograms/ml in ticks 
(Igboechi and Osazuwa1988). 
 
The combination of the plant species, icacina trichantha, ananas cosmos and uraria 
picta are also used for the treatment of diabetes. There are no publications on the 
anti-diabetic effects of the plants. This study is being undertaken to investigate the 
traditional evidence of the blood sugar lowering properties and the use of icacina 
trichantha, ananas cosmos and uraria picta in the treatment of diabetes.  
 
2.4.3 Ananas cosmos (Family,Bromeliaceae) 
The plant belongs to the same family as the popular pineapple Ananas comosus 
(family Bromeliaceae) and in most documentations, they are ascribed the same 
botanical name. The two plants are however different in size, with the normal 
pineapple being bigger in size and sweeter in taste. For the purpose of the present 
studies, the plant has been identified as Ananas cosmos with a preserved voucher 
specimen. The plant is grown in different parts of the world. 
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The formulation for the above named plants was obtained from a Nigerian herbalist 
(Mr. Adeyemi, 19 Igbobi college road, Shomolu, Lagos) who had used them 
extensively for a number of years to treat and manage diabetes with positive blood 
sugar control results. In one particular elderly patient, her personal physician after 
examining and taking her blood sugar level was amazed at the results. On further 
questioning, his patient confirmed to him that she was on herbal medication. The 
doctor advised her to continue with the treatment as it gave her more relief than the 
allopathic prescriptions. 
 
There is no formal documentation of these plants or the combination of the three 
plants being used to treat or manage diabetes mellitus therefore, it needs to be 
investigated more formally.  
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CHAPTER 3 MATERIALS AND METHODS  
 
3.1  Preparation of plant material 
 
The plants used in this study Icacina tracantha (tuber) (fam. Icacinaceae), Ananas 
cosmos (fruit) (fam. Bromeliaceae), and Uraria picta (leaves) (fam. Papilionaceace), 
were procured from a market in Mushin, a suburb in Lagos, Western Nigeria.  
 
The plants where not randomly procured. The procedure for procuring the plants from 
Mushin market was undertaken to simulate the procedure of the traditional herbalist, 
who regularly buys plants from the same seller who in turn obtains the plants from 
villages in a particular geographical area. Advice was sought from the traditional 
healers in terms of which sellers have the most efficacious plants.  
 
The plants were identified at the Institute for Tropical Agriculture, Ibadan, Oyo State, 
Nigeria and voucher specimens were deposited for reference and preservation at the 
institute’s herbarium. The three herbal medicinal plants were studied individually and 
in combination for their effects in a rat animal model of insulin resistance. 
 
3.1.1 Equipment used for extraction of aqueous crude extracts from the 
plants 
 
- Mettler PM4600 weighing scale.Mettler-Toledo AutoChem Inc., 7075 Samuel Morse 
Drive, ColumbiaMD, 21046USA  
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- 250ml glass beakers Boeco, Germany 
 
 
- Drying oven, Memmert Schwabach, Germany 
 
 
- Standard laboratory Bunsen burner, 
 
- Brannan Mercury thermometer. S. Brannan & Sons Ltd, England 
 
 
- 3000ml Pyrex beakers, Pyrex. 
 
- Labcon low temperature incubator. Labmark Laboratory Marketing Services (Pty) 
Ltd, Roodepoort, Johannesburg, South Africa. 
 
 
3.1.2 Procedure for preparation of crude plant extracts 
 
A 1.25 kg batch of dried macerated individual herbs was weighed using a Mettler 
PM4600 balance, washed in 5 litres of distilled water and the water was then 
removed by filtering the cleaned plant material through a sieveof aperture size, 
710µm.The clean plant was placed in a 3 litre beaker. Distilled water was added to 
cover the plant in the beaker.  The beaker containing the plant and distilled water was 
then heated and allowed to boil at a temperature of 100oC for 2 hours. Distilled water 
was added intermittently to ensure the plant material was always covered. The 
preparation was allowed to stand at ambient temperature and cool for about 12 
hours. It was then filtered with a sieve of aperture size, 710µmand the filtrate 
containing the plant extract was poured into a number of pre – weighed 250ml 
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beakers (Boeco, Germany) and allowed to dry in the oven at a temperature of 50oC 
until the filtrate was evaporated to dryness leaving the crude plant extract.  
 
The quantity of the plant extract obtained from the plant was determined by 
calculating the difference between the weight of the pre – weighed beakers and the 
weights of the beakers containing the dried plant extract. The dried extract was 
stored at a temperature of 4oC in a Labcon low temperature incubator for appropriate 
use when the doses were formulated and administered to the animals as required.  
The extraction ratio was determined using the weight of the extract as a percentage 
of the original dried plants. This method of extraction was adopted to simulate the 
traditional method of extracting the plants. This procedure was carried out in 
obtaining crude extracts for all the plants used in this study. 
 
To obtain a mixture of the plant extracts, the plants were combined based on the ratio 
used for treating diabetic patients as used in the traditional herbal clinic in Nigeria. 
Thus, 3 parts of Uraria picta to 2 parts Ananas cosmos to 1 part of Icacina tracantha 
was weighed, combined and extracted as described previously.  
 
3.2 Toxicity studies. 
 
Toxicity studies were conducted to ascertain the safe doses of the plant extracts to 
be administered to the rats in this study. This was necessary because previous work 
on the plants has only been able to identify the acute toxicity doses of some of the 
plants (Igboechi and Osazuwa, 1988, 1989; Asuzu and Abubarkar, 1995; Asuzu and 
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Ugwueze, 1990) whereas the present study involved the chronic administration of the 
plant extracts for a period of three weeks. 
 
 
Two toxicity studies were conducted. The first study was performed using doses of 
IIcacina tricantha  of 100mg/kg, Ananas cosmos of 200mg/kg, and Uraria picta of 
300mg/kg body weight. These doses were chosen based on published acute toxicity 
studies (Igboechi and Osazuwa, 1988, 1989; Asuzu and Abubarkar, 1995; Asuzu and 
Ugwueze, 1990). 
 
When the plant extracts were actually tested for their ability to improve glucose 
tolerance it was found that the Ananas cosmos and Uraria picta both lowered glucose 
concentration during the OGTT in the rats receiving the normal rat chow diet but had 
no effect on the animals receiving the high calorie diet. The IIcacina tricantha  had no 
effect in either group of animals. It was therefore decided to give the high calorie diet-
fed animals higher doses of Ananas cosmos and Uraria picta. Therefore, a second 
toxicity study had to be performed to ensure that these higher doses (600 mg/kg of 
AC and 800 mg/kg of Uraria picta) were safe. 
 
For the first toxicity study, nine male Sprague-Dawley rats weighing approximately 
300 grams were used. The animals were divided into groups of three animals per 
group.The maximum dose of the extracts (100mg/kg for IT, 200mg/kg for Ananas 
cosmos, and 300mg/kg body weight for Uraria picta) to be administered per kilogram 
body weight in the main study was administered to the animals daily for three weeks.  
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For the second toxicity studies using higher doses of Ananas cosmos and Uraria 
picta, four animals were used to reduce the suffering and death on the animals as a 
first toxicity test had been performed earlier. The animals were divided into two 
groups of two animals each, with each group being allocated to each plant extract. 
The animals were then given the allocated doses of the different plant extracts orally 
for 3 weeks at doses to be used in the main experiment. All the animals were dosed 
daily for the period of 3 weeks. During this period, the animals were observed for 
symptoms, rate of movement, general activity, behavioural changes and death.  
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3.3 Preparation of rats for extract dosing 
 
Male Sprague-Dawley (SD) rats weighing between 200 – 240 grams (217.45 ± 13.57) 
were used for the investigation of the possible anti-diabetic activity ofIcacina 
tricantha, Uraria picta and Ananas cosmos.  
 
Two to three rats were housed in each cage (n=2 or 3). All cages were numbered for 
proper identification, while all animals were marked with water resistant makers on 
their tails. The marking of the tail was done weekly to ensure that the animals could 
be properly identified. 
 
After 1 week of acclimatization to the facility, feeding of the animals commenced. The 
first batch of animals (n=54) was made up of the control animals fed on normal rat 
chow. All animals were weighed before the commencement of feeding. Animals were 
then allowed free access to food and water for the next four months. All animals were 
weighed monthly.  This same procedure was applied to the animals given the high 
calorie diet. 
 
3.3.1 Recipe for the special diet 
 
The second experimental batch of animals (n=66) was fed on a special high calorie 
diet. The diet consisted of 1.32kg of normal rat chow, 812ml of distilled water, 280 
grams of brown sugar (Selati® golden brown sugar) and 4 cans of normal condensed 
milk (Clover® condensed milk, 370 grams) that was mixed together to produce a 
homogenous paste. The paste was fed to the animals daily in a bowl. All rats in this 
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experimental group were placed on the diet for four months. This formulation was 
made every three days and the remnant discarded to avoid the growth of fungus.  
 
 
 
 
 
 
 
Table 3.0: Estimated nutritional value of the high calorie diet. 
At the end of the feeding period of four months, all the animals were randomly divided 
into groups containing six animals (n=6) per group as shown in table 3.1. For the next 
three weeks of the dosing of the rats with the various doses of the plant extracts, food 
consumption was measured and calculated. It was done to also determine the effect 
of the plant extract on the quantity of food consumed by the animals. For the animals 
fed on the normal rat chow, the feed in the cages was weighed before it was given to 
the animals and then the remnant weighed every three days.  Enough food was left to 
last beyond the 3 day period. The difference in weight between the initial quantity of 
food and the remnant was calculated and was taken as the food consumed by the 
animals in the cage. After taking measurement of the food consumed, fresh food was 
weighed to replenish the consumed food. This figure was divided by the number of 
animals per cage and by the number of days to estimate the quantity of food 
consumed by each animal per day it is assumed that each rat consumes roughly the 
Food description 
 
Calorie (cal) 
 
Carbohydrate from sugar 6591 
Carbohydrate other from plant sources 3595 
Protein 2032 
Fats 2835 
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same amount of food. For the animals on the special diet, the food consumed was 
measured by first weighing the bowl and then weighing the bowl with the feed paste. 
After the three day period when the feed was changed and freshly prepared feed 
introduced, the bowl and the remnant feed was weighed and the difference was 
divided by the number of animals per cage and by the number of days to give the 
average feed consumed by the animals per day.   
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Table 3.1: Group of rats and the daily dosing regimen administered. 
 
Doses of plant extracts administered number of animals 
per group 
Group A: Normal rat chow group: 
Icacina tracantha  
50 mg/kg body weight 6 
100 mg/kg body weight 6 
  
Uraria picta  
150 mg/kg body weight 6 
300 mg/kg body weight 6 
  
Ananas cosmos  
100mg/kg body weight 6 
200mg/kg body weight 6 
  
Ananas cosmos/Icacina tracantha/Uraria picta (300 
mg/kg) combination 
6 
92BReference groups  
Metformin (Sigma - Aldrich) 300mg/kg 6 
Control group (on water only) 6 
Sub Total 54 
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Group B: High calorie diet group. no of animals per 
group 
Icacina tracantha  
50 mg/kg body weight 6 
100 mg/kg body weight 6 
  
Uraria picta  
150 mg/kg body weight 6 
300 mg/kg body weight 6 
800mg/kg body weight 6 
  
Ananas cosmos  
100mg/kg body weight 6 
200mg/kg body weight 6 
600 mg/kg body weight 6 
  
Ananas cosmos/Icacina triacantha/Uraria picta 
(300 mg/kg) combination 
6 
Reference Groups  
Metformin group 300mg/kg daily 6 
Special diet control group (on special diet only) 6 
Sub Total 66 
Total number of animals used 120 rats. 
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3.4 Weighing of animals 
After feeding for a period of four months, dosing commenced. During the period of 
dosing, all animals were weighed on a weekly basis using a Mettler PM4600 
electronic scale.  
 
3.5 Dosing animals 
After the animals were weighed, doses of the plant extract to be administered were 
calculated and formulated per body weight for each of the animals. This was done by 
dissolving the plant extract in distilled water, making the appropriate concentration 
and determining the dose to be administered. The animals were then each given the 
calculated dose of the plant extractdaily between 7 – 10 am in the mornings by oral 
gavage with the aid of a dosing needle and syringe for 3 weeks. The doses given of 
each plant extract are shown in Table 3.1. 
 
Before the commencement of dosing with the different plant extracts, 1ml of blood 
was collected from the cleaned tail of each animal. This was necessary to have a 
baseline reading for the plasma blood samples from each animal. Weekly, 1 millilitre 
of blood was collected from the tail vein of all the animals with the help of the 
veterinary nurses and animal technicians of the central animal unit.  
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This temperature was maintained with the aid of a thermometer and constantly 
adding more ice. This was done to inhibit the breakdown of the glucose in the blood 
as no anti - glycolytic agent was used at this stage (Annelise et al, 1998). 
 
The blood in the Eppendorf tubes were centrifuged at 3000g using a Sorvall T6000D 
centrifuge and plasma collected by carefully extracting with a pipette. The collected 
plasma was stored in sterile 1.5ml Eppendorf tubes at a temperature of   – 72 0 C in a 
Sanyo Ultra low temperature freezer (Model - U4086S) until further analysis. 
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3.7 Oral glucose tolerance test 
 
3.7.1 Material and equipment 
 
Accu-check active glucometer (Roche Diagnostics, Basel, Switzerland) 
 
Accu-check active glucometer strips (Roche Diagnostics, Basel,  
 
Switzerland) 
 
Glucose obtained fromSaarchem chemicals, South Africa. 
 
Dosing needle and 5 ml syringes (SURGI PLUS), swab, and distilled  
 
water. 
 
250 millilitre beakers, Pyrex, 200 millilitre flask Schott Duran  
 
Balances:  Mettler – Toledo AB104 – S, Mettler PM4600. 
 
3.7.2 Experimental procedure for measurement of glucose concentration 
After the daily dosing period of three weeks and weekly collection of blood, an oral 
glucose tolerance test (OGTT) was carried out on all the animals. All rats were fasted 
overnight and the following morning2g/kg body weight of glucose solution was 
administered to each animal by oral gavage.  
 
Increased glucose concentrations have been associated with diabetes mellitus. An 
OGTT is used to determine the ability of the body to metabolize and clear glucose out 
of the blood stream. The test can be used to determine and diagnose diabetes. 
Administering the test after the period of dosing will help determine the effect of the 
plant extract on glucose clearance. Where the plant extracts have the ability to 
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improve glucose clearance rate, it is expected that the area under the curve for the 
plant extract will be lower compared to the control.   
 
Blood glucose concentrations were measured by pricking the tail tip and using an 
Accu-check active (Roche Diagnostics, Basel, Switzerland) blood glucose meter to 
take the readings. The glucose level was read by allowing a drop of blood from each 
animal’s tail to drip on the glucometer strip (Accu-Chek active strips, Roche) inserted 
into the glucometer. The glucose concentration was then read and documented from 
the glucometer readings. This method was chosen because it used a very small 
quantity of whole blood (<5 μl) and gave immediate results and thus an indication of 
whether the glucose load had been administered successfully via gavage. Results 
were not repeated due to the high cost of the Acu-Check strips and ethical 
considerations of not putting rats under more stress than what is required. After the 
initial measurement of blood glucose was taken using the glucometer (at time 0), 
glucose was administered orally to each rat. Blood glucose concentrations were then 
measured at 30, 60, and 120 minutes after the loading dose of 2g/kg glucose was 
given. 
 
One day after the completion of the OGTT, all animals were anesthetized, 5ml of 
blood was collected using cardiac puncture into grey BD Vacutainer bottles and 
portions of the liver, left soleus and gastronimus muscles, pancreas, and abdominal 
fat tissues were collected into 1.8 ml cryogenic tube vials, (Nunc, Denmark). This was 
done to collect final blood samples and relevant tissues (liver, muscles and fat) that 
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will further help to shed more light on the effect of the plant extracts on glucose, 
insulin and free fatty acid in the body. 
 
3.8 Euthanizing of animals and harvesting of tissues 
This procedure was performed under the guidance of the staff of the University of the 
Witwatersrand animal house.  
 
3.8.1 Anesthetizing and euthanizing procedure 
 
A mixture of ketamine (80mg/kg body weight) and xylazine (40mg/kg body weight) 
was used to euthanize the animals. The anaesthetic was administered 
intramuscularly.  
3.8.2 Collection of final blood samples and harvesting tissues 
 
After the animals were anesthetized, 4mls of blood was collected via cardiac 
puncture with a needle and a 5 ml syringe into grey BD Vacutainer bottles. Each tube 
was gently shaken to ensure proper mixing of the blood with the anti-coagulant 
before centrifuging.  
 
Using a surgical blade, a pair of scissors and forceps, each animal was dissected and 
portions of liver, left soleus and gastronimus muscles, pancreas, and abdominal fat 
tissues were collected into 1.8 ml cryogenic tube vials, (Nunc, Denmark) and quickly 
snap frozen in liquid nitrogen in a Dewar flask and stored at – 72 0 C in a Sanyo Ultra 
low temperature freezer, (Model - U4086S) for further analysis.  
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The tissues were identified with the help of the consultant veterinarians at the 
University of the Witwatersrand Central Animal Unit. The collected blood was 
collected into grey BD Vacutainers and processed as mentioned in section 3.6. 
3.9 Analysis of plasma samples for glucose concentration using the 
Quantichrom glucose assay kit 
The procedure was carried out using the Quantichrom glucose assay kit using 96-well 
plates. The kit was procured from BiosAssay Systems, Hayward, United States. 
Catalogue number DIGL-100, DIGL-200. This method was chosen to measure 
glucose concentration during the period when the animals were being treated with the 
plant extracts. 
 
In the diabetic state, the glucose concentration in the body is elevated and needs to 
be normalized. While the OGTT is performed to determine the clearance rate of 
glucose from the blood, the analysis of the plasma for glucose concentration helps to 
determine the effect of the plant extracts during the three week dosing period on the 
mobilization of glucose from the blood into the storage organs, the muscles and the 
liver. It is expected that plant extracts that have anti-diabetic properties will show a 
reduced concentration of glucose in the blood plasma compared to the control, 
indicating that the plant extract have a greater ability to mobilize glucose compared to 
the control group. The lower this concentration, the more efficacious the plant is in 
performing this function. Thus, this test is needed to help investigate the diabetic 
action of the plants. 
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3.9.1 Material and equipment used 
Labsystem finnipettepipette. Labsystem 
Multiple pipette dispenser (Eppendorf multipetter plus). 
Disposable tips. 
1.5 and 2.0mL Eppendorf centrifuge tubes 
Orbital plate shaker. 
Tube holder. 
Labcon water bath. 
-20 o C freezer 
96 well plate, Sero-Wel, Bibby Sterillin Ltd, U.K. 
Labsystems Multiskan Ascent automatic plate reader. (Labsystem Inc. United States) 
3.9.2 Experimental procedure 
 
 
The 1.5mL Eppendorf centrifuge tubes were set up in a tube holder. Following this 5 
μL diluted standard glucose solution from the manufacturer’s kit for the standard 
curve, and plasma samples from each rat, were transferred into appropriately 
labeledEppendorf tubes using the mutipipette dispenser and disposable tips. This 
was followed by the transfer of 500 μL of reaction reagent (1)from the glucose assay 
kit into each tube using a multiple pipette dispenser (Eppendorf multipetter plus). 
 
The tubes were tightly closed and thoroughly mixed by shaking andthen placed in the 
tube holder and heated in a boiling water bath (Labcon) for 8 min. After 8 min, the 
tubes were cooled down in a cold water bath for 4 min at 4 0 C. Then, 200 μL of the 
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contents of each of the tubes were transferred using a pipette (Labsystem finnipette 
pipette) with attached tip into each well in a clear bottomed 96-well plate, while 
avoiding the formation of bubbles. The plate was read at a wavelength of 650nm. 
Actual glucose concentration in the individual rat plasma samples was calculated 
from the optical density readings by using equation 3.1 below. The results were 
converted to mmol/L. 
 
The optical density (OD) of the water blank was subtracted from the standard OD values 
and these were plotted against the known standard concentrations that came with the kit. 
The slope was determined using linear regression fitting. Because the standard curve 
went through the origin, the glucose concentration in each plasma sample is calculated 
as in equation 3.1. 
 
Glucose concentration = UOD SAMPLE – OD BLANK  (mg/dLU)  Equation 3.1  
                              Slope 
 
Where ODSAMPLE and ODBLANK are optical density values of the plasma samples and 
“blank” samples respectively. 
3.10 Analysis of insulin concentration in rat plasma samples 
Insulin the hormone responsible for the mobilization of glucose from the blood is 
necessary to help maintain normal glucose concentration. In the present experiment, 
the animals have been fed a high calorie diet that leads to high concentration of 
insulin and insulin resistance. If the concentration of insulin is not normalized 
overtime, type II diabetes sets in. Substances that help bring down the concentration 
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of insulin and improve the mobilization of glucose into the cells may be described as 
having anti-diabetic effect. In the present experiment, lower concentration of insulin 
over time by any of the plant extracts in comparison to the control is an indication that 
the plant extracts have glucose lowering effects 
3.10.1 Material and equipment used 
 
High Range Rat Insulin ELISA, catalogue number 10-1145-01, Mercodia, AB, 
Labsystem finnipette pipette.(Labsystem Inc. United States). 
Multiple pipette dispenser (Eppendorf multipetter plus).Uppsala, Sweden. 
Disposable tips. 
Orbital shaker and incubator for plates. 
BioTek ELX 50 automated strip washer. 
Labsystems Multiskan Ascent automatic plate reader.(Labsystem Inc. United States)  
3.10.2 Experimental procedure 
 
The concentration of insulin in the rat plasma samples for all the animals was 
analyzed by using High Range Rat Insulin ELISA, catalogue number 10-1137-01 
procured from Mercodia, AB, Uppsala, Sweden. A 5 µl sample of plasma from each 
ratwas introduced into each well of a 96 well plate, using a Labsystems finnipette 
pipette with a disposable tip.  
 
A 5 μl aliquot of each calibrator was also added to the appropriate wells in the 96 well 
plate. This was followed by the addition of 50 μl enzyme conjugate solution to all the 
wells. 
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The plate was incubated on a plate shaker at 700 – 900 rpm for 2 hours at a 
temperature of 240 C. The 96 well plates was then washed using a BioTek ELX 50 
automated strip washer, six times. After the final wash, the plate was blotted on a clean 
tissue to ensure that the plate was dry and then200 μl of the substrate, TMB was added 
to each well. The plate was further Incubated for 15 minutes and50 μl of stop solution 
was then added and the plate was put on the shaker for about 5 seconds to ensure 
thorough mixing of the contents. After mixing, each plate was read using a Labsystems 
Multiskan Ascent Spectrophotometer plate reader at 450nm. The actual insulin 
concentration in the plasma samples were calculated from the spectrophotometer 
readings using the standard curve determined from the supplied calibrators. The results 
were recorded as μU/mL. 
 
3.10.3 Calculation of Insulin sensitivity 
 
Insulin sensitivity in each animal was calculated using the homeostasis model 
assessment (HOMA-IR) formula: 
 Fasting insulin (μU/mL) × fasting glucose (mmol/L)/22.5.Equation 3.2 
 
Low HOMA-IR values indicate greater insulin sensitivity, and higher HOMAR-IR 
values indicate lower insulin sensitivity (insulin resistance).  
3.11 Analysis of free fatty acid concentration in rat plasma samples 
Because obesity and dyslipedemia are associated with diabetes, the ability of the 
plant extracts to improve the lipid profile by reducing the concentration of free fatty 
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acid in comparison to the control group is an indication of the anti-diabetic properties 
of the medicinal plants. 
  
3.11.1 Equipment and reagents. 
Roche kit: free fatty acids, half – micro test, Cat No 1383175 
Table 3.11.1a Content of kits 
Bottle  Contents  
1  5 x 11 ml each of potassium phosphate buffer, pH 7.8  
2  5 tablets,each tablet contains: ATP, coenzyme A, acyl-
CoA-synthetase (Acyl CS), peroxidase, ascorbate 
oxidase, 4-aminoantipyrine and stabilizers.  
3  3 mlof aqueous N-ethyl-maleinimide solution with 
stabilizers. Note: The presence of N-ethyl-maleinimide in 
the test is necessary for the removal of an existing 
surplus of CoA before the oxidation of the activated fatty 
acids by ACOD.  
4  5 x approx. 0.6 ml of ACOD dilution solution and 
stabilizers.  
5  5 tabletsand each tablet contains: acyl-CoA-oxidase 
(ACOD) and stabilizers  
 
 96 – microwell plate Sero – Well ( Bibby Sterilin Ltd, Stone Staffs, U K) 
96 well plate, Sero-Wel, Bibby Sterillin Ltd, stones U. K. 
Eppendorf multipettor  
Accurate pipettes for 10ul volumes 
Orbital shaker and incubator for plates. 
Labsystems Multiskan Ascent automatic plate reader 
3.11.2 Procedure 
 
The manufacturer’s protocol was followed and used in this procedure. All the 
solutions and reagents were mixed and prepared as described in the kit.Using a pair 
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of forceps to transfer the tablets from the bottles, reaction mixture A was prepared by 
dissolving one tablet from bottle 2 in the solution in bottle 1. Reaction mixture B was 
prepared by dissolving one tablet of bottle 5 in the solution in bottle 4. The prepared 
solutions were stored at 4o C in a Labcon low temperature incubator. This was used 
up within 3 days as the prepared solutions do not remain stable for long.  
 
A standard solution of palmitate, was prepared as documented in the manufacturer’s 
kit.Thus, working solution 1 was made by dissolving 6.0 g of Triton X-100 (BDH. 
Poole, England)  in about 80 ml of warm double distilled water in a 200ml beaker 
(30°-40°C), allowed to cool to 15-25°C and made up to 100 ml in a measuring 
cylinder. Next, 9 mg palmitic acid was weighed using a Mettler – Toledo AB104 – S 
balance, introduced into a 100 ml beaker and dissolved in about 6 ml of warm ethanol 
(about 35 – 40 °C). The beaker was immediately sealed with parafilm and allowed to 
cool to 15 – 25 °C to make working solution 2. 
 
The two working solutions were combined to create the standard palmitc acid solution 
which is stable for only 3 days in a refrigerator. A 10 µl aliquot of blank (double 
distilled water), standard and samples were distributed into the wells of a 96 well 
plate using an Eppendorf pipette with disposable tips. Next, 200μlof solution A was 
added into each well using an Eppendorf multipettor plus.  
The plate was then placed on the orbital plate shaker and incubator (around 500 – 
800 rpm), and incubated at a temperature of 25 0 C for 10 minutes. After incubation, 
10 µl of N-ethyl-maleinimide stop solution was added into all the wells to stop the 
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reaction. The plate was then mixed shortly on the shaker and absorbance read at 540 
nm using a plate reader (Labsystems Multiskan Ascent), (A1). The plate was returned 
to the shaker for 20 minutes after which readings were taken again using the plate 
reader (A2). The difference in absorbance readings (A2 - A1) for all the samples, 
including both blank and sample was calculated. The absorbance difference of the 
blank (ΔAb) was then subtracted from the absorbance difference of the sample 
(ΔAS). This gives (ΔA)the concentration of free fatty acid in each plasma sample as 
shown by equation 3.3. 
ΔA =ΔAS – ΔAb     Equation 3.3 
 
 3.12 Statistical analyses 
 
Area-under-the-curve (AUC) values for glucose during the OGTT were calculated 
using the trapezoid rule.  Fasting and AUC glucose concentrations were compared 
across groups using 1-way ANOVA ..  
 
At baseline (i.e. before administration of the plant extracts), significant differences 
were observed between the rat groups for the mean values of nearly all the variables 
under analysis. Thus, for the normal diet fed animals the minimum and maximum 
mean baseline values for body weight, glucose, free fatty acids, insulin and HOMA for 
each of the 9 treatment groups were as follows: 600-697 g; 5.1-7.2 mmol/l; 0.61-1.23 
mmol/l; 3.86-6.32 μIU/ml; 0.83-1.87. For each of these variables, except insulin, 
ANOVA demonstrated a statistically significant difference across the 9 groups of 
animals.  For the high calorie diet fed animals the minimum and maximum mean 
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baseline values for body weight, glucose, free fatty acids, insulin and HOMA for each 
of the 11 treatment groups were as follows: 592-651 g; 4.98-10.35 mmol/l; 0.67-1.68 
mmol/l; 13.3-45.3 μIU/ml; 3.3-18.2. For each of these variables, except body weight, 
ANOVA demonstrated a statistically significant difference across the 9 groups of 
animals.Therefore, to correct for the differences observed at baseline, the data 
collected at weeks 1, 2 and 3 was expressed as a % of the baseline values 
 
Statistical analysis, within treatment groups, of data collected at baseline, 1, 2 and 3 
weeks was carried out using repeated measures ANOVA. Analysis of data across 
treatment groups at each time point was performed using a 1-way ANOVA. The post 
hoc test used for comparing paired means after both ANOVAs, was Tukey’s  test. 
This test was chosen as it reduces the risk of type 1 errors occurring. 
 
The AUC was calculated for all data collected over the 3 week treatment period and 
values were compared between normal diet fed and high calorie diet fed animals 
using a 2-way ANOVA.  This analysis was used to determine if any interaction occurs 
between the treatments and the diet for each measured variable i.e. food intake, body 
weight, glucose, FFA, insulin and HOMA levels. Each treatment group was compared 
with the control group in each of the 2 different diet groups.   
 
Although much of the data displayed a non-Gaussian distribution analysis of the 
mean values with parametric or non-parametric statistical tests gave very similar 
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results. The p-values given in the Results section all come from the use of parametric 
statistical analyses. 
 
Statistica v9.1 (StatSoft, Tulsa, OK, USA) was used for all statistical analyses. 
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CHAPTER 4  RESULTS 
 
4.11Toxicity tests 
After the 3 week period of dosing with the plant extracts all the rats in the two toxicity 
tests showed no signs of distress, discomfort and no deaths were recorded.All the 
animals were adjudged healthy by the animal house veterinarian. Approval was 
granted for the commencement of the work. 
4.12 Extraction of plant extracts 
 
The maceratedpart of each plant was extracted to obtain the crude extract when 
needed or when the previous extract had been used up.  In this study only 2 batches 
were required to conclude the experiments. 
Table 4.1. Extraction percentage for each plant extract. 
 
Plant Batch 
Dried 
plant 
weight (g) 
Weight  
of extract 
(g) 
Extraction 
percentage 
(%) 
IT tuber a 93.46 41.61 44.52 
 
b 145.15 66.50 45.81 
Mean 
 
119.31 54.06 45.17 
STD 
 
36.55 17.60 0.91 
Ananas 
cosmos fruit 
a 95.37 33.48 35.11 
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b 155.55 65.12 41.87 
Mean 
 
125.46 49.30 38.49 
STD 
 
42.55 22.37 4.78 
Uraria picta 
leaves 
a 97.73 30.94 31.67 
 
b 149.52 55.12 36.84 
Mean 
 
123.63 43.03 34.26 
STD 
 
36.62 17.10 3.66 
Mixed a 93.52 30.86 33.00 
 
b 163.50 65.37 40.00 
Mean 
 
128.51 48.12 36.50 
STD 
 
49.48 24.40 4.95 
 
Table 4.1. Gives the average solute extracted from each dried macerated plant 
extract and a mixture of the plant extracts. Extracts were carried out in batches 
indicated as “a” and “b”. As can be seen from table 4.1,the percentage extracted of 
each plant were very similar for the two batches. Batch “a” was used for the normal 
diet fed animals and batch “b” was used for the high calorie diet fed animals. 
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Table 4.1a Differences between HCD and normal diet fed animals at 
baseline 
 
Variable Normal diet fed rats 
(N=53) 
High calorie diet fed rats 
(N=66) 
Body weight (g) 643 ± 55 623 ± 55* 
Fasting glucose 
(mmol/l) 
6.30 ± 1.11 7.17 ± 2.29* 
Fasting insulin (uIU/ml) 4.98 ± 1.67 33.0 ± 15.0*** 
 
Data is expressed as mean ± SD; *p<0.05, ***p<0.0005 versus normal diet fed rats 
 
Table 4.1a shows differences at baseline, for body weight, fasting glucose and fasting 
insulin concentration between the normal diet fed and the high calorie diet fed 
animals. Body weight was slightly higher in the normal diet fed animals whilst fasting 
glucose and insulin concentration were significantly higher in the high calorie diet fed 
animals. 
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        Figure B: High calorie fed    
 Figure 4.1.1.  Bar chart showing the percentage median weight in the normal diet  
fed  animals  (A) and the high calorie diet fed animals (B) in control, metformin and mixture 
groups of rats over 3 weeks of dosing with the of plant extracts. 
 ap<0.05, bp<0.005, cp<0.0005 vs baseline .xp<0.05, y p<0.005, zp<0.0005 vs controls. 
 
 
 
4.1 Weight of rats during the period of dosing in normal fed and HCD 
diet fed rats. 
Figures 4.1.1 – 4.1.4 show the median percentage weight of the normal diet fed 
animals (A) and the high calorie diet fed animals (B) for control animals and all 
treatment groups.   
 
 
           
            
         Figure A: Normal diet fed 
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   Figure A: Normal diet fed 
 
Figure B: High calorie fed 
 
Figure 4.1.2 Bar chart showing the percentage median weight in the normal diet fed 
animals  (A) and the high calorie diet fed animals (B) in  control, IT50 and IT100 
groups of rats over 3 weeks of dosing. 
ap<0.05, bp<0.005, cp<0.0005 vs baseline  
xp<0.05, y p<0.005, zp<0.0005 vs controls. 
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Figure A: Normal diet fed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure B: High calorie fed. 
 
Figure 4.1.3.  Bar chart showing the percentage median weight in the normal diet          
fed animals  (A) and the high calorie diet fed animals (B) in  control, AC100, AC200 and 
AC600 groups of rats over 3 weeks of dosing. 
ap<0.05, bp<0.005, cp<0.0005 vs baseline  
xp<0.05, y p<0.005, zp<0.0005 vs controls. 
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 Figure B: High calorie fed 
  ap<0.05, bp<0.005, cp<0.0005 vs baseline  
  xp<0.05, y p<0.005, zp<0.0005 vs controls. 
 Figure 4.1.4 Bar chart showing the percentage median weight in the normal diet      
fed animals  (A) and the high calorie diet fed animals (B) in control, UP150, UP300 
and UP800 groups of rats over 3 weeks of dosing 
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4.1 Description of body weight results. 
 
In figure 4.1.1, the body weight of the normal diet fed rats did not change with time 
whilst in the high calorie diet animals, body weight fell. Metformin was observed to 
significantly bring down the weight of the animals in the normal diet fed group of 
animals. While there was weight reduction with metformin in the high calorie diet, this 
was not significantly different to that observed in the control animals. The mixed 
extract brought about significant weight loss in the second week when compared with 
the control and baseline data in the normal diet fed rats. In the high calorie diet fed 
animals, the mixed extracts significantly reduced the weight of the animals in the 
second and third weeks when these values are compared to baseline concentration 
but at both these time points, weights were higher than in the control animals. These 
results are confirmed by 2-way ANOVA where a significant interaction was observed 
between the mixed plant extract and dietary intake (F=8.7, p=0.008) on the area-
under-the-curve data for body weight (%).  
 
In figure 4.1.2, IT50 and Icacina tricantha  100 did not have any effects on growth, in 
both the normal diet fed and high calorie diet fed animals, when compared to that 
seen in the control animals.  
 
Figure 4.1.3 shows that in the normal diet group, Ananas cosmos100 reduced weight 
over time but the effect was not significantly different from that seen in the control 
animals, whilst Ananas cosmos200 had a minimal effect. The effect of the Ananas 
cosmosplant extract on growth in the high calorie diet fed  group was also minimal, 
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with no significant effect observed when compared against the control group. Figure 
4.1.4 shows that in normal diet fed rats, Uraria picta 150 and 300 produced  a 
sustained weight loss in comparison to both baseline levels and control animals. In 
the high calorie diet fed animals, Uraria picta treatment had minimal effects on weight 
when compared to the control group of animals. This differential effect of Uraria picta 
on weight in the normal diet and high calorie diet fed group fed animals is confirmed 
by 2-way ANOVA, where significant interactions are found between  Uraria picta use 
and diet for both 150 (F=39.8, p<0.0001) and 300mg (F=6.2, p=0.02) doses for AUC 
data for body weight. 
 
75 
 
4.2 Food intake results in normal fed and HCD diet fed rats. 
Figures 4.2.1 – 4.2.4show the median percentage food intake in the normal diet fed 
 animals (A) and the high calorie diet fed animals (B).for control animals and  
all treatment groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Figure A: Normal diet fed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
          
          Figure B: High calorie fed 
 
         Figure 4.2.1 Bar chart showing the percentage median food intake in the normal  
           diet fed animals  (A) and the high calorie diet fed animals (B) in control, metformin  
            and mixed groups of rats over 3 weeks of dosing.                   
           
           ap<0.05, bp<0.005, cp<0.0005 vs baseline xp<0.05, y p<0.005, zp<0.0005 vs controls. 
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             Figure 4.2.2. Bar chart showing the percentage median food intake in the normal  
  diet fed animals (A) and the high calorie diet fed animals (B) in control, IT50 and IT100    
  groups of rats over 3 weeks of dosing. 
                      ap<0.05, bp<0.005, cp<0.0005 vs baseline  
            xp<0.05, y p<0.005, zp<0.0005 vs controls. 
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      Figure A: Normal diet fed  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             Figure B: High calorie fed 
 
 Figure 4.2.3 Bar chart showing the percentage median food intake in the normal diet fed  
animals (A) and the high calorie diet fed animals (B) in control,  AC100, AC200 and AC600  
groups of rats over 3 weeks of dosing. 
 
ap<0.05, bp<0.005, cp<0.0005 vs baseline  
xp<0.05, y p<0.005, zp<0.0005 vs controls. 
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Figure A: normal diet fed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
             Figure B: High calorie fed 
 
              Figure 4.2.4  Bar chart showing the percentage median food intake in the normal  
              diet fed animals (A) and the high calorie diet fed animals (B) in control, UP150, UP300,  
              and UP800 groups of rats over 3 weeks of dosing. 
 
                     ap<0.05, bp<0.005, cp<0.0005 vs Baseline  
                     xp<0.05,yp<0.005, z p<0.0005 vs controls.  
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4.2 Description of feeding results. 
 
In figure 4.2.1, food intake fell over time in the control, normal diet fed animals and in 
the control group of the high calorie diet fed animals. Metformin did not have any 
significant effect on the quantity of food consumed by the animals receiving the 
normal diet or the high calorie diet. In the animals fed the mixed plant extracts, food 
intake in both the high calorie diet and normal diet fed groups was higher than in the 
controls at week 2 and week 1, respectively. 
 
In figure 4.2.2, animals receiving the normal diet had their food intake increased by 
IT50 compared to baseline and control concentration by week 2, whilst in the high 
calorie diet animals Icacina tricantha 50 reduced food intake by week 2. These data 
are confirmed by 2-way ANOVA where a significant interaction between Icacina 
tricantha  50 use and dietary treatment on AUC levels of food intake was observed 
(F=14.9, p=0.008). The Icacina tricantha 100 had no significant effects. 
 
In Figure 4.2.3, the Ananas cosmos plant extract had no effect on food intake in the 
normal diet fed animals whilst in the high calorie diet animals, food intake was 
increased by Ananas cosmos200 above control concentration by week 2. 
 
In figure 4.2.4, Uraria picta 150 increased food intake relative to the control animals in 
both the normal diet and the HCD fed animals, by week 2. 
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4.3 Glucose concentrations in normal fed and HCD diet fed rats. 
Figures 4.3.1 – 4.3.4 show the median percentage of glucose concentration in the 
normal diet fed animals (A) and the high calorie diet fed animals (B) for control 
animals and all treatment groups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
          Figure A: Normal diet fed 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
              
         Figure B: High calorie fed 
 
        Figure 4.3.1 Bar chart showing the percentage median glucose concentration in    
the normal  diet fed animals (A) and the high calorie diet fed animals (B) in control,              
metformin and mixed groups over 3 weeks of dosing. 
           ap<0.05, bp<0.005, cp<0.0005 vs Baseline 
           xp<0.05,yp<0.005, z p<0.0005 vs controls. 
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  Figure B: High calorie fed 
    
 Figure 4.3.2 Bar chart showing the percentage median glucose concentration in  
 the normal  diet fed animals (A) and the high calorie diet fed animals (B) in control,  
 IT50 and IT100 groups over 3 weeks of dosing. 
 
 ap<0.05, bp<0.005, cp<0.0005 vs Baseline  
 xp<0.05,yp<0.005, z p<0.0005 vs controls.  
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Figure A: Normal diet fed   
 
 
 
 
 
 
 
       
         
         
         
         
         
         
         
         
         
         
         
         
 Figure B: High calorie fed    
       
Figure 4.3.3 Bar chart showing the percentage median glucose  concentration in the 
normal  diet fed animals (A) and the high calorie diet fed animals (B) in control, AC100, 
AC200, and AC600 groups over 3 weeks of dosing.     
   ap<0.05, bp<0.005, cp<0.0005 vs Baseline  
    xp<0.05,yp<0.005, z p<0.0005 vs controls.  
 
  
0
50
100
150
200
250
Baseline week 1 week 2 week 3
Gl
uc
os
e 
le
ve
l (
%
) c
om
pa
re
d 
to
 b
as
el
in
e 
Time (week) 
Control
AC 100
AC 200
a 
c 
 
y 
0.00
50.00
100.00
150.00
200.00
250.00
300.00
350.00
Baseline week 1 week 2 week 3
Gl
uc
os
e 
le
ve
l (
%
) c
om
pa
re
d 
to
 b
as
el
in
e 
Time (week) 
Control
AC 100
AC 200
AC 600
a 
x 
b 
y 
b 
 
b 
z 
a 
83 
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   Figure B:High calorie fed    
 
                       Figure 4.3.4 Bar chart showing the percentage median glucose concentration  
                            in the normal diet fed animals (A) and the high calorie diet fed animals (B) in control,               
                            UP150, UP300 and UP800 groups over 3 weeks of dosing.    
 
ap<0.05, bp<0.005, cp<0.0005 vs Baseline  
    xp<0.05,yp<0.005, z p<0.0005 vs controls.  
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4.3 Description of glucose results. 
 
In figure 4.3.1, glucose concentration rose above baseline concentration in the 
normal diet fed control animals whilst in the high calorie diet group glucose 
concentration were not significantly different from baseline values in the control 
group. In the normal diet fed animals, metformin significantly reduced the blood 
glucose concentration relative to the control animals by the last week of treatment, 
but had no significant effect in the high calorie diet fed animals. The mixed plant 
extract in the normal diet fed animals had no significant effect on glucose  
concentration when compared to the control animals, whilst the mixed plant extract 
significantly increased blood glucose concentration in the high calorie diet animals 
when compared with both baseline and control concentration. This differential effect 
of the mixed extract on glucose levels is also shown in a 2-way ANOVA where a 
significant interaction was observed between use of the mixed extract and dietary 
treatment on AUC glucose levels (F=15.0, p=0.0009). 
 
In figure 4.3.2, Icacina tricantha 50 was shown to reduce glucose concentration 
relative to control animals in those rodents receiving the normal diet but this effect 
was seen only at week 2. No effect of either doses of Icacina tricantha was observed 
in the high calorie diet animals relative to the control group. 
 
In figure 4.3.3, in the normal diet fed animals, Ananas cosmos 100 reduced blood 
glucose concentration significantly when compared to the control animals but this 
effect was observed only at week 2. A similar trend was observed with Ananas 
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cosmos 200 but the 2-week effect was not significant. In the high calorie diet group, 
Ananas cosmos100 and Ananas cosmos200 treated animals had blood glucose 
concentrations that were significantly higher than baseline and control values at week 
1 and 3 for Ananas cosmos200 and at week 1 for Ananas cosmos100. This 
differential effect of Ananas cosmos on blood glucose in the two different diet groups 
was confirmed by the presence of a statistically significant interaction between 
Ananas cosmos use and AUC data for dietary intake for both the 100mg (F=12.4, 
p=0.002) and 200mg (F=7.2 and p=0.01) doses of Ananas cosmos. 
 
Data from figure 4.3.4 show that in the normal diet fed animals the Uraria picta plant 
extract had no significant effect on blood glucose concentration compared with the 
control animals, whilst in the high calorie diet group, Uraria picta800 significantly 
lowered the glucose concentration compared to the baseline level and the control 
animals, at week 3. This differential effect of Uraria picta on glucose levels in the 2 
different diet groups was again confirmed by 2-way ANOVA, where a significant 
interaction between Uraria picta150 use and diet (F=5.7, p=0.03) for AUC data for 
glucose, was observed. 
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4.4 Insulin concentrations in normal fed and HCD fed rats 
Figures 4.4.1 – 4.4.4show the median percentage insulin concentration of the normal 
diet fed animals (A) and the high calorie diet fed animals (B) for control animals and 
all treatment groups.   
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     Figure B: High calorie fed     
     Figure 4.4.1 Bar chart showing the percentage median insulin concentration in the  
     normal diet fed animals (A) and the high calorie diet fed animals (B) in control, metformin  
     and mixed groups over 3 weeks of dosing.  
    ap<0.005, bp<0.0005, cP<0.0001 vs Baseline     x p<0.005,y p<0.0005,z<0.0001  vs controls. 
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Figure B: High calorie fed
 
Figure 4.4.2 Bar chart showing the percentage median insulin concentration in the 
normal  diet fed animals (A) and the high calorie diet fed animals (B) in control, IT50 
and IT100 groups over 3 weeks of dosing.  
 
ap<0.005, bp<0.0005, cP<0.0001 vs Baseline  
xp<0.005,y p<0.0005,z<0.0001  vs controls 
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Figure B: High calorie fed     
 
Figure 4.4.3 Bar chart showing the percentage median insulin concentration in the 
normal  diet fed animals (A) and the high calorie diet fed animals (B) in control, AC100, 
AC200 and AC600 groups over 3 weeks of dosing.  
  ap<0.005, bp<0.0005, cP<0.0001 vs Baseline  
  xp<0.005,y p<0.0005,z<0.0001  vs controls.  
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        Figure B: High calorie fed 
 
Figure 4.4.4. Bar chart showing the percentage median insulin concentration in the 
normal  diet fed animals (A) and the high calorie diet fed animals (B) in control, UP150, 
UP300 and UP800 groups over 3 weeks of dosing. 
 
  ap<0.005, bp<0.0005, cP<0.0001 vs Baseline  
  xp<0.005,y p<0.0005,z<0.0001  vs controls.   
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4.4 Description of insulin results. 
 
Figure 4.4.1 - 4.4.4 shows the effects of the plant extracts on insulin concentration in 
both normal fed and high calorie diet fed rats.  
 
Figure 4.4.1 shows that in the normal diet fed animals, insulin concentration 
increased with time in the control group whilst in the metformin treated group, insulin 
concentration fell dramatically from baseline concentration and then increased slowly 
but still remained below control concentration. In the high calorie diet fed animals, 
insulin concentration did not change significantly over time in the control group whilst 
in the metformin treated animals, insulin concentration did fall over time and were 
lower than in the control group but none of the differences were statistically 
significant. 
 
All the plant extracts in the normal diet fed group produced significant reductions in 
the concentration of insulin both over time and in comparison to the control animals.  
In the high calorie diet animals, the mixed plant extracts had no significant effect on 
insulin concentration (Figure 4.4.1B)  whilst Icacina tricantha  at all doses (Figures 
4.4.2B) significantly reduced insulin concentration compared to control animals and 
baseline concentration at week 2 and 3.The Ananas cosmos100 and AC200 extracts 
significantly reduced insulin concentration relative to control animals and baseline 
concentration at weeks 2 and 3, whilst AC600 had minimal effects (Figure 4.4.3B). 
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Figure 4.4.4B shows that in the high calorie diet animals Uraria picta150 and Uraria 
picta300 both reduced serum insulin concentration significantly when compared to 
control animals and to baseline insulin concentration at weeks 2 and 3, but Uraria 
picta800 had no such effect. 
 
All the plant extracts (excluding the mixed extract) seem to reduce insulin levels to a 
greater extent in the normal diet compared to the high calorie diet fed animals. This is 
confirmed by 2-way ANOVA where significant interactions between plant extract use 
and dietary treatment on AUC insulin levels were observed for Icacina tricantha  
50mg (F=6.4, p=0.02) and 100mg (F=5.2, p=0.03), Ananas cosmos 100 (F=4.4, 
p=0.048) and 200mg (F=6.3, p=0.02) and Uraria picta 150 (F=5.8, p=0.02) and 
300mg (F=5.4, p=0.03).  
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4.5 HOMA values in normal fed and HCD fed rats 
Figures 4.5.1 – 4.5.4 show the median percentage of HOMA values of the normal diet 
fed animals (A) and the high calorie diet fed animals (B) for control animals and all 
treatment groups 
 
 
 
  Figure B: High calorie fed 
 
Figure 4.5.1 Bar chart showing the percentage median HOMA values in the normal  
diet fed animals  (A) and the high calorie diet fed animals (B) in control, metformin and 
mixed plant extracts groups over 3 weeks of dosing. 
  
  ap<0.005, bp<0.0005, cP<0.0001 vs Baseline 
            x p<0.005,y p<0.0005,z<0.0001  vs controls. 
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Figure A: normal diet fed 
 
 
 
 
                                 Figure B: High calorie fed 
Figure 4.5.2 Bar chart showing the percentage median HOMA values in the normal  
diet fed animals   (A) and the high calorie diet fed animals (B) in control, IT50 and IT100 
plant crude extract groups over 3 weeks of dosing. 
  ap<0.005, bp<0.0005, cP<0.0001 vs Baseline  
  xp<0.005,y p<0.0005,z<0.0001  vs controls.   
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Figure 4.5.3 Bar chart showing the percentage median HOMA values in the normal  
diet fed animals   (A) and the high calorie diet fed animals (B) in control, AC100,AC200 
and AC600 doses of crude plant crude extract groups over 3 weeks of dosing. 
 
  ap<0.005, bp<0.0005, cP<0.0001 vs Baseline  
  xp<0.005,y p<0.0005,z<0.0001  vs controls.   
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Figure A: Normal diet fed 
 
 
 
 
 
  Figure B: High calorie fed 
 
Figure 4.5.4 Bar chart showing the percentage median HOMA values in the normal  
diet fed animals   (A) and the high calorie diet fed animals (B) in control, UP150, UP300 
and UP800 doses of crude plant crude extract groups over 3 weeks of dosing. 
 
  ap<0.005, bp<0.0005, cP<0.0001 vs Baseline  
  xp<0.005,y p<0.0005,z<0.0001  vs controls.    
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4.5 Description of the effect of plant extract dosing on insulin sensitivity. 
 
Figures 4.5.1 - 4.5.4 describe the effect of the plant extracts on insulin sensitivity.  
The data for the effects of the plant extracts and metformin on HOMA concentration 
in both the normal diet and high calorie diet fed animals are exactly the same as 
those observed for insulin concentrations. This is not surprising, as HOMA and insulin 
concentration correlate very significantly. The 2-way ANOVA results observed with 
AUC insulin levels were also replicated for the HOMA AUC data, demonstrating that 
the plant extracts had greater effects on reducing HOMA in the normal diet than in 
the high calorie diet fed animals. Thus, significant interactions between extract use 
and HOMA levels were observed for Icacina tricantha  50mg (F=7.6, p=0.01) and 
100mg (F=4.7, p=0.04), Ananas cosmos 100 (F=7.5, p=0.01) and 200mg (F=8.4, 
p=0.009) and Uraria picta 150 (F=6.3, p=0.02) and 300mg (F=5.5, p=0.03).     
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 Figure B: High calorie fed 
 
Figure 4.6.1. Bar chart showing the percentage median FFA values in the normal diet fed 
animals   (A) and the high calorie diet fed animals (B) in control metformin and mixed doses of 
crude extract groups over 3 weeks of dosing. 
 
 ap<0.05, bp<0.005, cp<0.0005 vs baseline;  
 xp<0.05, yp<0.005 vs control. 
  
4.6 Free fatty acid concentrations in normal and HCD diet fed rats 
Figures 4.6.1 – 4.6.4Shows the median percentage of FFA values of the normal diet fed 
animals (A) and the high calorie diet fed animals (B) for control animals and all treatment 
groups. 
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 Figure B: High calorie fed 
 
Figure 4.6.2 Bar chart showing the percentage median FFA concentration in the normal  
diet fed animals   (A) and the high calorie diet fed animals (B) in control IT50 and IT100  
doses of crude extract groups over 3 weeks of dosing. 
  
 ap<0.05,  vs baseline 
 xp<0.05, vs control. 
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  Figure B: High calorie fed 
 
 Figure 4.6.3 Bar chart showing the percentage median FFA concentration in  
 the normal diet fed animals   (A) and the high calorie diet fed animals (B) in control  
 AC 100, AC200, and AC600 doses of crude extract groups over 3 weeks of dosing. 
 
  ap<0.05, bp<0.005, cp<0.0005 vs baseline;  
  xp<0.05, yp<0.005 vs control. 
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 Figure B: High calorie fed 
   
Figure 4.6.4 Bar chart showing the percentage median FFA concentration in the  
normal diet fed animals   (A) and the high calorie diet fed animals (B) in control  
UP150, UP300, and UP800 doses of crude extract groups over 3 weeks of dosing. 
 
ap<0.05, bp<0.005, cp<0.0005 vs baseline;  
xp<0.05, yp<0.005 vs control. 
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4.6 Description of free fatty acid (FFA) results. 
Figure 4.6.1 shows the serum FFA concentration in the control animals and the effect 
of metformin and the mixed plant extract on FFA concentration in the normal diet fed 
and high calorie diet fed animals. In the control animals on the normal diet, FFA 
concentration rose significantly above baseline values at week 1 but fell back down to 
baseline concentration by week 3. There was no significant change in FFA 
concentration over time in the high calorie diet fed control animals. Metformin 
significantly reduced the concentration of FFA in the normal diet fed ratswhen 
compared to the control group, but only at week 1. In the high calorie diet fed 
animals, there was no significant effect of metformin on FFA concentration.  The 
mixed plant extracts had no effect on FFA concentration in either the normal diet fed 
or high calorie diet fed animals when compared to the relevant control groups.In 
figure 4.6.2, Icacina tricantha 50 and IT100 did not significantly affect the FFA 
concentration in the normal diet fed animals. The same pattern was observed for the 
Icacina tricantha 50 in the high calorie diet group however, the Icacina tricantha 100 
extract in the high calorie diet animals significantly reduced the concentration of FFA 
when compared to the control and baseline values, but only at week 2. 
 
In figure 4.6.3, AC200 in both the normal diet fed and the high calorie diet HCD fed 
animals significantly reduced FFA concentration compared to control animals at week 
1 in the normal diet fed and at week 2 in the high calorie diet fed animals. The other 
doses of AC had no significant effects.  
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Figure 4.6.4 shows that the Uraria pictaextract did not show any significant effect on 
FFA concentration in either the normal diet fed or the high calorie diet fed animals, 
when compared to the appropriate control group of animals. 
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4.7 Oral glucose tolerance test results in normal and HCD diet fed group. 
Figures 4.7.1 – 4.7.4 show the OGTT results for the normal diet fed animals (A) and 
the high calorie diet fed animals (B) for control animals and all treatment groups. 
 
 
 
 
 
 
 
 
 
 
 
Figure A: Normal diet fed 
 
 Figure B: High calorie fed 
Figure 4.7.1 shows the glucose clearance rate in normal diet fed animal (A) and high calorie diet fed 
animals(B) in control, metformin and mixed groups  
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Figure A: Normal diet fed 
 
 
Figure B: High calorie fed 
Figure 4.7.2. shows the glucose clearance rate in normal diet fed animal (A) and high 
calorie diet fed animals(B) in control, IT50 and IT100. 
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           Figure A: Normal diet fed 
 
 
 
     Figure B: High calorie fed 
Figure 4.7.4 shows the glucose clearance rate in normal diet fed animal (A) and high calorie diet fed 
animals (B) in control, UP150, UP300 and UP800 groups 
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4.7 Description of the effect of plant extracts in animals during the OGTT. 
 
Figures. 4.7.1 – 4.7.4describe the effects of the plant extracts on glucose 
concentration during an OGTT in both groups of animals. The results obtained from 
the OGTT showed that the extracts had a greater effect on glucose clearance in the 
animals fed on normal rat chow compared to the animals fed the high calorie diet 
(HCD).  
 
Metformin and the mixed plant extracts had no effect on glucose concentration in 
either the normal diet fed or the high calorie diet fed groups of animals (Figure 4.7.1). 
This was also the case for all doses of Icacina tricantha  (Figure 4.7.2). However, in 
the normal diet fed animals AC200 produced lower fasting glucose concentration and 
total (AUC) glucose concentration when compared to both control and AC100 
animals (Figure 4.7.3). No effect of Ananas cosmos was seen in the high calorie diet 
animals. Figure 4.7.4 shows that in the normal diet fed animals, Uraria picta300 
produced significantly lower fasting glucose concentration when compared to the 
control animals and those treated with Uraria picta150. Also, total (AUC) glucose 
concentration were significantly lower in the Uraria picta150 and Uraria picta300 
treated animals than the control animals. No effect for the Uraria picta plant extract 
was observed in the high calorie diet fed animals. 
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CHAPTER 5 DISCUSSION 
 
5.11 Selection of doses of plant extracts 
 
The choice of doses for the plant extracts was made based on the literature and 
traditional herbal medicinal use of the plants (Igboechi and Osazuwa, 1988, 1989; 
Asuzu and Abubarkar, 1995; Asuzu and Ugwueze, 1990). Doses lower than the 
acute toxicity doses for the plant extracts were used. Also, the ratio for the 
formulation of the mixed plant extracts was chosen based on the ratio used by a 
herbalist. From traditional medicinal use, Uraria picta and Ananas cosmos are known 
to be quite safe while I. trichanthais known to have emetic effects. In fact Uraria picta 
is consumed as a vegetable by some cultures in Nigeria. The metformin dose of 
300mg/kg was chosen based on several publications including that by Nobuyuki et al 
(2004). The plant extract doses used in this study are similar to the traditional 
medicinal doses except that in traditional herbal medicinal use, the patient is asked to 
take the aqueous extract three times daily. In this study, the plant extracts were 
administered only once daily. 
 
5.12 Toxicity and safety studies 
 
Before the commencement of the main studies and approval by the animal ethics 
committee, permission was given to conduct safety and toxicity studies to ascertain 
the safe doses of the plant extracts to be used in the studies. Two studies were 
conducted. In both studies, the highest possible doses of the extracts to be 
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administered were given to the animals daily for three weeks. In both studies, the 
extracts were found to be safe to be administered at those doses as no death was 
recorded and the animals did not show any adverse symptoms during the period of 
observation. 
 
5.13 Effect of plant extracts on food intake and body weight 
 
 
It has been established that feeding different species of animals on high calorie diets 
of varying formulations for different durations leads to insulin resistance but not 
diabetes (Chalkey et al, 2002). The severity of insulin resistance in animals is highly 
affected by the diet composition, duration of feeding and the animal species. Rats 
have been known to produce wide variations in fasting plasma glucose concentration 
with associated hyperglycaemia, (Han et al, 1997), variations in insulin concentration 
between the normal diet fed group and high calorie diet fed animals (Noshiro et al, 
1997) and different responses in terms of weight gain.  
 
Even though there is no perfect animal model that totally simulates the physiological 
and biochemical effects in humans of diabetes and obesity, most models are still able 
to provide valuable information (Cefalu, 2006). 
 
Among out-bred Sprague Dawley rats fed on a high fat diet, “approximately one-half 
develop diet-induced obesity (DIO) and one-half are diet resistant (DR) on a diet 
relatively high in fat and energy content (HE diet)” gaining weight and fat at the same 
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rate as chow-fed controls however having increased fat pad, higher insulin and leptin 
concentration when compared to animals fed on normal rat chow (Levin et al, 1997, 
Levin and Keesey, 1998).  
 
In the present study, the animals were fed on a high sucrose diet. The estimated 
percentage of sucrose in the diet is 18 %. 
 
Kanazawa et al (2003) reported that feeding rats on a high sucrose (60% sucrose) 
diet for 2 weeks does not induce obesity in lean rats or enhance weight gain in obese 
rats. Santuré et al, 2002demonstrated that, after 4 weeks of feeding, rats displayed 
comparable final body weight regardless of whether they had been fed high sucrose 
or the normal chow diet. However, the average daily ad libitum intake was 
significantly lower for the sucrose-fed rats compared to their control chow-fed rats. 
Long term feeding of rats for up to 42 weeks on a high sucrose diet (63% sucrose) as 
reported by Fortino et al (2006), induced dyslipidemia, glucose intolerance, and 
adiposity. 
 
Rats fed on a high sucrose diet were also observed to consume lesser amounts of 
food when compared to animals fed on the normal rat chow. (Fortino et al (2006) 
 
In this study, the animals were fed for 16 weeks before dosing with the plant extracts 
commenced. The average weight of the animals fed on the high calorie diet was 
observed to be slightly lower than those of rats fed the normal rat chow before dosing 
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with the plant extracts. Despite this, the high calorie diet fed animals had higher 
insulin and glucose concentration than the normal diet fed animals before the plant 
extracts were administered to them, a result similar to that reported by other authors 
(Levin et al, 1997, Levin and Keesey, 1998). Also, weight gain is affected and 
determined by the diet composition and the duration of feeding. Lombardo et al 
(1996) showed that weight gain in rats fed on a rich sugar diet for the first 15 weeks 
did not differ between groups. A significant increase in weight gain was however 
observed in animals fed from 15 – 30 weeks. In the present study, the animals were 
fed for 16 weeks before dosing.  
 
Meformin was observed to bring about a sustained decrease in the body weight of 
the animals in the normal diet fed group without affecting food intake. This correlates 
with the known effect of metformin to reduce weight in obese and diabetic rats (Bailey 
et al, 1996).Chronic administration of metformin (300mg/kg, subcutaneously 
administered) in obese Zucker rats, has been shown to significantly reduce food 
intake in rats whereas, 150mg/kg had no effect. In this experiment, 300mg/kg body 
weight of metformin was administered orally. The same group of researchers 
reported that intragastric administration of metformin did not have any effect on the 
food intake in rats. Data collated in this study correlates with these findings, as 
metformin was observed to bring about the sustained reduction of weight and oral 
dosage of metformin was observed not to affect food intake. (Rouru et al, 1995) 
In the present study, the mixed plant extracts and Uraria picta150 caused greater 
weight gain in high calorie diet animals when compared to the control group. This 
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may be explained by higher food intake in these animals. However, in the normal diet 
fed groups, these plant extracts caused weight loss relative to the control groups, 
despite increased food intake relative to the control animals. These differential effects 
of the plant extracts in high calorie diet and normal diet fed animals are interesting 
and suggest that the extracts have effects on metabolism that are altered directly or 
indirectly by dietary intake. Energy expenditure was not measured in this study so we 
cannot make any conclusions on whether the weight effects of the plant extracts are 
mediated by effects on energy expenditure. The Ananas cosmos plant extract also 
caused weight loss relative to the control animals, but had no effect on food intake.  
Other studies have shown that medical plants decrease body weight in rats (Tian et 
al 2004) and the ability of some of the plant extracts to decrease body weight 
portends a possible functionality in the improvement of type II diabetes associated 
with obesity and weight gain (Bailey et al, 1996). 
 
The average daily food intake in the animals in this study is comparable to that 
documented by Ace Animals Inc. (website reference 6), a breeder of Sprague Dawley 
rats in the United States. This is given as approximately 30grams/day.  
 
5.14 Effect of plant extracts on glucose concentration 
  
It has been established in a number of studies that feeding rats on a high sucrose 
concentration diet leads to glucose intolerance, a condition that predisposes to type II 
diabetes (Lombardo and Chicco, 2006). The present study also shows that, prior to 
113 
 
dosing with the plant extracts, glucose concentration were higher in the high calorie 
diet fed rats compared to the normal diet fed animals, despite the former group 
having a slightly lower mean body weight.  
 
In this study, the effect of the different plant extracts on plasma glucose concentration 
in both normal fed and high calorie diet fed rats was evaluated. Plant extracts are 
known to elicit different responses in rat plasma glucose (Gallagheret al, 2003). 
Grover et al (2002) reviewed over 40 Indian medicinal plants that have shown both 
hypoglycemic and anti-hyperglycemic activity.Some plant extracts have been shown 
to act by abolishing the activities of glucose-6-phosphate dehydrogenase and 6-
phosphate gluconate dehydrogenase in the intestinal mucosa-epithelial tissue (IMET) 
and liver (Netzer et al, 2003). 
 
The metformin treatment in the normal diet fed group led to a significant reduction in 
glucose concentration in the last week when compared to the control group, whilst 
metformin in the high calorie diet group caused no significant change in glucose 
concentration although they did tend to be lower than the concentrations observed in 
the plasma of the control animals at week 1 and week 3. It is possible that the dose of 
metformin used in the high calorie diet group was too low to bring about a significant 
change in glucose concentration.  
 
The effect of dosing with the different plant extracts on blood glucose varied in the 
different groups of animals. Some extracts did reduce blood glucose concentration 
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when compared to the control animals e.g. Ananas cosmos100 in the normal diet fed 
group but only at week 2 and Uraria picta800 in the high calorie diet animals, but only 
by week 3. Other extracts actually increased glucose concentration e.g. Ananas 
cosmos (AC) 100 and AC200 in the high calorie diet group and the mixed extracts at 
weeks 1 and 3 in the high calorie diet fed animals. However, these effects were small 
when compared to the changes observed in insulin concentration for animals treated 
with the plant extracts (see next section).  
 
The fluctuation of the glucose concentration during the period of dosing may be an 
indication that the plant extracts contain glucose lowering substances, but not in 
sufficient quantities to maintain a sustained reduction in glucose concentration. Also, 
the possibility that in some animals, glucose concentration rose due to the massive 
reduction in insulin concentration caused by the plant extracts will be discussed in the 
next section.  
 
A major reason why the plant extracts could not bring the glucose concentration 
under control may be due to inadequate dosages and the route of administration. 
Rouru et al, (1995) has demonstrated that chronic administration of metformin 
subcutaneously improves efficacy of the drug. Oral administration exposes the 
extracts to a first pass effect leading to lesser availability of the drug. Also, in 
traditional herbal medicinal use, divided doses of the plant extracts are taken three to 
four times every day while dosing was carried out once daily every morning in the 
rats. These factors could negatively impact on the potency of the extracts. 
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5.16 Effect of plant extract dosing on insulin and insulin sensitivity 
 
The results clearly show that the plant extracts significantly improve insulin sensitivity 
and insulin concentration in both normal diet fed and high calorie diet fed animals. 
This effect was sustained in both the normal fed and high calorie diet groups of 
animals. When compared to the control group and baseline values, the ability of the 
plant extracts to bring down insulin concentration was observed to be the most 
prominent effect of the extracts. By default, the reduced insulin value also impacts on 
the HOMA value, which is used to determine insulin sensitivity. 
 
A number of studies have established the induction of hyerinsulinemia and reduced 
insulin sensitivity in animals fed on high fat and high sucrose diets over a long period 
of time (Fortino et al, 2007). Data collated from this study is also in support of this 
trend. Basal insulin concentration and HOMA values in high calorie diet animals, 
before commencing treatment with the plant extracts, were observed to be five to 
seven times higher than those in the normal diet fed animals. These results are also 
supported by a number of studies where animals have been fed on high fat, high 
sucrose diets (Kawasaki et al 2005, Noshiro et al 1997). 
 
In the control animals during the 3 week dosing period, insulin and HOMA 
concentration increased over time in the normal diet fed animals and this may 
represent the well-known effect of aging on insulin resistance. However, in the high 
calorie diet rodents, insulin concentration did not change over time and this may be 
partially explained by the fall in body weight observed in these animals over the 
116 
 
course of the experiment. Metformin treatment led to major reductions in insulin and 
HOMA concentration in the normal diet fed rats, whilst concentration were also lower 
in the high calorie diet animals, the effect was not significant. Metformin is a well-
known insulin sensitiser, so these effects were not unexpected.    
 
It is interesting to note that the effect of the plant extracts on insulin concentration 
was observed in the normal diet fed rats within the first week of administering the 
extracts whilst in the high calorie diet animals the effect was observed only after 2 
weeks. This may be due to the higher baseline insulin and HOMA concentration 
observed in the high calorie diet animals.  This delayed response to the plant extracts 
in the high calorie diet fed animals may explain the 2-way ANOVA results where 
significant interactions were observed between plant extract use and insulin and 
HOMA AUC levels.  
 
The mixed plant extract did not have a significant effect on insulin concentration in 
the high calorie diet animals. It should also be noted that Ananas cosmos (AC)100 
and AC200 caused increases in blood glucose in the high calorie diet animals. This is 
possibly not due to the massive effect on the attenuation of insulin  concentration 
since AC100 increased glucose concentration at week 1 but there was no parallel 
reduction in insulin concentration. Also, at week 3 similar reductions were observed in 
insulin concentration for Ananas cosmos (AC)100 and AC200 yet only in the AC200 
animals did glucose concentration rise significantly above control concentration. 
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Because plants contain a number of active constituents that are soluble in particular 
solvents and can be extracted using different solvents, different results may be 
expected depending on the extraction procedure used on the plants. Studies by 
Phuong et al, (2004) on the petroleum ether extract of Nigella sativa seeds on blood 
glucose, insulin and lipids in normal rats brought about a reduction of insulin but had 
no effects on glucose.  
 
This is an indication that the plant extracts administered to the rats were able to 
improve the capacity of the cells to respond to insulin.In traditional herbal medicine 
the use of poly herbal medication is quite common place (Dixit et al, 
1999,Sachidananda et al 2001).  
 
5.17 Effect of plant extract dosing on free fatty acids. 
 
The serum FFA concentration rose above baseline values in the control, normal diet 
fed animals, at week 1 but fell back to baseline by week 3. No changes in FFA 
concentration were observed in the high calorie diet animals. Metformin did reduce 
FFA concentration in the normal diet fed animals at week 1 but the effect was not 
sustained. Metformin would be expected to reduce FFA concentration as it is an 
insulin sensitising agent and would thus augment the ability of insulin to inhibit 
triglyceride lipolysis.   
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Apart from IT100 and Ananas cosmos200whichsignificantly brought down the level of 
FFAs, but only transiently, the effect of the other plant extracts were not 
significant.This demonstrates that the effects of the plant extracts on insulin sensitivity 
were not mediated through effects on serum FFAconcentration. 
 
 
5.18 Effect of plant extract dosing on the OGTT. 
 
The results in this study demonstrate the glucose lowering effect of some of the plant 
extracts. The administered doses of Ananas cosmos and Uraria picta in the normal 
diet fed animals significantly improved the glucose clearance rates. None of the 
different plant extracts had any significant effect on the glucose clearance rate in the 
high calorie diet fed animals. 
 
While a number of medicinal plants have been shown to have hypoglycaemic effects 
and improve the glucose clearance rate in animals (Soo et al, 2009), studies such as 
those conducted by Al-Awadi FM. and Gumaa KA, (1986), investigating the 
antidiabetic effect of five Kuwaiti medicinal plants concluded that only two of the plant 
extracts showed glucose lowering effect using the OGTT. A similar pattern is seen in 
this study. 
 
The OGTT data suggests that the major effect of some of the plant extracts i.e. 
Icacina. trichantha is to improve insulin sensitivity but not to alter glucose 
concentration, whilst for Ananas cosmos and Uraria picta insulin sensitivity is 
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improved in conjunction with improved postprandial glucose clearance. It is possible 
that these different effects on glucose concentration are the result of the greater 
efficacy of Ananas cosmos and Uraria picta to improve insulin sensitivity when 
compared to IT. The lack of effect of the plant extracts on the OGTT glucose 
concentration in the HCD fed animals may be due to the high level of insulin 
resistance at baseline in these animals, with the plant extracts not able to sufficiently 
reduce this to a level that leads to improved glucose clearance.   
 
5.19 Clinical relevance of this study 
The high calorie diet did not lead to obesity or type 2 diabetes but it did have 
profound effects on insulin concentrations and more modest effects on glucose 
concentrations, as described earlier in this chapter. Thus, we were unable to produce 
a model of type 2 diabetes using this diet. However, the animals fed the high calorie 
diet certainly expressed a phenotype of insulin resistance. All the plant extracts, with 
the exception of the mixed extract, were able to attenuate the insulin resistance 
observed in this group of animals. This is a very important finding and suggests that 
the plant extracts may have insulin sensitising effects which would be very useful for 
treating human type 2 diabetes in which insulin resistance is one of the prime 
aetiological factors. Obviously, the efficacy of these plants in human diabetic subjects 
would need to be tested in a clinical trial, however the fact that these plants are used 
for treating diabetes in African populations suggests there may be some clinical 
benefit. Whether these plant extracts are able to improve the insulin secretory 
dysfunction that is observed in human type 2 diabetes is not known and would 
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require further investigations in other more appropriate rodent or in vitro model 
systems. 
 
The active ingredients of the extaracts that ameliorate insulin resistance  need to be 
isolated and characterised. This may lead to the development of possible new 
therapies for diabetes, as the isolation of metformin from the French lilac so ably 
demonstrates.  
      
5.20 Limitation of the study. 
 
1. The present study was characterised by a number of limitations including the 
following: 
 
2.  The sample size of 6 rats per group is rather small.  It is possible that this may 
have led to an inability to detect more subtle changes in a number of the investigated 
parameters, particularly food intake and glucose levels.  
 
3. Even though rodents have been widely used and acknowledged as acceptable 
experimental animals, results and findings from studies like this cannot be transposed 
to humans. 
 
4. The animals in this study did not develop type 2 diabetes and therefore we cannot 
show that the plant extracts ameliorate the metabolic dysfunction associated with this 
disorder. The use of diabetic Zucker rats or other similar rodent models of type 2 
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diabetes may clarify this. However, the animals fed the high calorie diet did develop 
profound insulin resistance, which is a key component of type 2 diabetes.  
 
5. Better methods of extraction like freeze drying may have been employed to extract 
the active ingredients of the plants. The process employed in this research entailed 
drying the solution in an oven for days until dryness. This process may have 
denatured some of the active constituents of the plant extracts. Better methods of 
purification of the crude extracts could have also been employed to obtain a purer 
extract. 
 
6. Working with plant extracts poses a lot of challenges peculiar to phyto-chemical 
research. It is an established fact that the pharmacological activities of plants are 
governed and affected by a number of factors including weather, soil composition, 
time and season of harvesting, method of storage, and processing and preservation. 
Even though the researcher endeavoured to secure plants from a particular seller at 
a particular month, these parameters may still have affected the efficacy of the plant 
extracts. Two different batches of plant extracts were used in this study and it is 
therefore possible that batch-to-batch variation may have affected some of the 
outcomes of this study. 
 
7. The mechanisms by which these extracts reduce insulin sensitivity was not 
explored in the present study. Therefore, we cannot clearly state that the extracts 
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have direct effects on insulin sensitivity. It is possible that the extracts act indirectly or 
are metabolised to agents that effect insulin activity. 
 
8. The plant extracts did not produce a clear dose response on some of the 
measured variables. The reasons for this are uncertain, but an understanding of their 
molecular modes of action may help to clarify this response. 
 
9. The plant extracts were crude and the active ingredients are not known. Further 
work is required to purify the active ingredients and characterise them.  
 
10. Measurements of variables analysed during the dosing period were not made 
during the 4 months when animals were being given the normal or high calorie diet. 
Measurements were made at baseline but data on body weight and food intake would 
have been useful to see how the 2 diets affected both these parameters in the run-in 
to the dosing experiments.  
 
11. The measurement of HbA1c was not performed. This may have given some 
information on the level of glucose tolerance in each treatment group before the plant 
extracts were administered and would also have given useful information on the level 
of postprandial glycaemia during the dosing period.  
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5.21 Conclusions 
 
The plants used in the present studies were observed to be safe for use in all the 
animals, even in large doses. This present study also suggests that the crude plant 
extracts may have value in modifying insulin resistance, a syndrome that predisposes 
to type II diabetes.  
 
The stated aims of the research were achieved.  The individual plant extracts in 
normal diet fed animals were observed to lower insulin concentration and improve 
insulin sensitivity. In the high calorie diet fed animals, a similar pattern of lowering the 
concentration of insulin plasma concentration and improving insulin sensitivity was 
observed. The combination of the plant extract was not as efficacious as the 
individual plant extracts. In comparison to metformin, some of the plant extracts were 
observed to have a greater insulin-sensitising effect.  
 
The effect of the plant extracts on FFA concentrations and weight was minimal. From 
the data collated and analysed it can be seen that the plant extracts helped improve 
insulin resistance in the rats, suggesting that the plants may be used to prevent or 
improve insulin sensitivity in subjects predisposed to type 2 diabetes. However, these 
findings must be tested in human clinical trials.  
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Appendix 
Tables 
Table 4.1.1 weight of normal diet fed rats during the period of dosing. 
 
Group 
mg/kg Week Baseline 1 2 3 
Control (Rat code) 15a 682.00 702.50 692.00 693.00 
 
15b 595.00 597.50 597.50 590.00 
15c 550.00 535.50 535.50 537.00 
16a 531.00 548.00 548.00 548.00 
16b 602.00 615.50 603.00 605.00 
16c 700.00 703.00 680.00 691.00 
Mean ± SD 610.00 ± 68.43 
617.00 ± 
72.79 
609.33 ± 
65.15 
610.67 ± 
67.89 
Median (%) 100.00 101.34 100.29 99.83 
Quartile Range 0.00 2.59 4.10 2.90 
      
Metformi
n 
24a 597.00 575.00 567.00 552.00 
 24b 534.00 514.00 494.00 489.00 
 24c 640.00 623.00 607.00 595.00 
 20a 631.00 613.00 601.00 567.00 
 20b 615.00 582.00 568.00 567.00 
 20c 586.00 566.00 550.00 537.00 
 Mean ± SD 600.50 ± 38.33 
578.83 ± 
38.76 
564.50 ± 
40.84 
551.17 ± 
36.02 
 Median (%) 100.00 96.45 94.35 91.92 
 Quartile Range 0.00 0.89 2.47 0.09 
      
Mixture 21a 680.00 650.00 635.00 672.00 
 21b 547.00 550.00 541.00 571.00 
 21c 725.00 726.00 724.00 739.00 
 22a 722.00 723.00 698.00 717.00 
 22b 619.00 616.50 573.00 620.00 
 22c 612.00 596.00 579.00 609.00 
 Mean ± SD 650.83 ± 70.31 
643.58 ± 
70.56 
625.00 ± 
73.63 
654.67 ± 
65.70 
 Median (%) 100.00 99.87 95.64 99.84 
 Quartile Range 0.00 2.75 5.50 2.62 
      
I T 50 2a 622.50 624.00 617.50 615.50 
 2b 573.50 570.50 568.50 565.00 
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 2c 629.00 622.50 623.00 615.50 
 1a 639.00 655.00 646.50 641.00 
 1b 640.00 646.00 643.00 647.00 
 1c 592.00 606.00 599.50 598.00 
 Mean ± SD 616.00 ± 27.20 
620.67 ± 
30.22 
616.33 ± 
29.11 
613.67 ± 
29.93 
 Median (%) 100.00 100.59 99.83 99.59 
 Quartile Range 0.00 2.89 2.10 2.50 
      
I T 100 3a 625.00 631.00 615.00 604.00 
 3b 676.00 677.00 670.00 666.00 
 4a 632.00 642.00 633.00 630.00 
 4b 627.00 645.00 633.50 627.50 
 4c 660.00 658.00 654.50 655.00 
 Mean ± SD 644.00 ± 22.77 
650.60 ± 
17.61 
641.20 ± 
21.33 
636.50 ± 
24.45 
 Median (%) 100.00 100.96 99.17 99.24 
 Quartile Range 0.00 1.43 1.05 1.16 
      
A C 100 13a 652.00 650.00 642.00 631.00 
 13b 705.00 702.00 692.50 695.00 
 13c 625.00 622.00 615.00 604.50 
 10a 667.00 667.00 663.00 660.50 
 10b 601.00 596.00 586.00 582.50 
 10c 570.00 567.00 556.50 559.50 
 Mean ± SD 636.67 ± 8.33 
634.00 ± 
49.08 
625.83 ± 
50.20 
622.17 ± 
50.33 
 Median (%) 100.00 99.55 98.13 97.54 
 Quartile Range 0.00 0.21 0.84 1.80 
      
A C 200 7a 669.00 671.00 672.00 669.00 
 7b 715.00 702.50 698.00 695.00 
 7c 598.00 607.00 596.00 600.00 
 9a 619.00 626.50 622.50 622.50 
 9b 616.00 610.00 606.00 607.50 
 9c 685.00 679.00 670.00 670.00 
 Mean ± SD 650.33 ± 46.11 
649.33 ± 
40.09 
644.08 ± 
41.44 
644.00 ± 
39.07 
 Median (%) 100.00 99.71 99.01 99.31 
 Quartile Range 0.00 2.19 2.64 2.52 
      
U P 150 18a 743.00 718.00 702.00 715.00 
 18b 692.00 653.00 634.50 648.00 
 18c 634.00 598.00 576.00 586.00 
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 19a 656.00 628.50 607.50 614.00 
 19b 692.00 668.00 652.00 661.00 
 19c 684.00 652.00 640.00 637.00 
 Mean ± SD 683.50 ± 37.13 
652.92 ± 
40.19 
635.33 ± 
42.52 
643.50 ± 
43.95 
 Median (%) 100.00 95.57 93.09 93.62 
 Quartile Range 0.00 2.17 2.52 2.39 
      
U P 300 6a 594.00 594.00 579.00 570.00 
 6b 724.00 701.00 707.00 716.00 
 6c 692.00 675.00 666.50 650.00 
 11a 695.00 677.50 662.00 671.00 
 11b 770.00 726.50 669.00 717.00 
 11c 705.00 675.00 718.00 678.00 
 Mean ± SD 696.67 ± 57.90 
674.83 ± 
44.49 
666.92 ± 
48.94 
667.00 ± 
54.29 
 Median (%) 100 97.15 96.89 96.07 
 Quartile Range 0 1.8 2.4 2.62 
 
 
 
Table 4.1.2 weight of high calorie diet fed rats during the period of dosing 
Group 
mg/kg Week Baseline 1 2 3 
Control 1a 656 640 615 605 
 1b 565 554 540 535 
 1c 567 560 550 556 
 2a 750 770 720 701 
 2b 648 633 603 595 
 2c 703 706 663 655 
 Mean ± SD 648.20 ± 73.41 
643.83 ± 
83.68 
615.20 ± 
68.30 
607.83 ± 
61.76 
 Median (%) 100.00 98.40 94.94 93.31 
 Quartile Range 0.00 2.74 2.25 2.47 
      
Metformin 3a 652 638 607 605 
 3b 725 720 694 690 
 3c 564 540 526 530 
 4a 628 531 508 510 
 4b 562 560 582 570 
 4c 620 618 582 580 
 Mean ± SD 625.20 ± 60.75 
601.20 ± 
72.28 
583.20 ± 
65.99 
580.83 ± 
63.59 
 Median (%) 100.00 98.58 93.57 93.76 
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 Quartile Range 0.00 3.90 2.63 2.38 
      
Mixture 5a 642 632 630 625 
 5b 662 648 640 633 
 5c 578 564 560 557 
 6a 562 578 556 554 
 6b 656 656 644 640 
 6c 672 672 666 659 
 Mean ± SD 628.67 ± 46.74 
625.00 ± 
44.00 
616.00 ± 
46.46 
611.33 ± 
44.70 
 Median (%) 100.00 99.22 98.15 97.46 
 Quartile Range 0.00 2.11 2.04 1.70 
      
I T 50 7a 610 606 588 579 
 7b 670 610 642 630 
 7c 666 666 634 629 
 8a 626 630 598 591 
 8b 652 662 620 610 
 8c 680 702 674 669 
 Mean ± SD 650.67 ± 27.33 
646.00 ± 
37.27 
626.00 ± 
31.27 
618.00 ± 
32.19 
 Median (%) 100.00 100.31 95.67 94.43 
 Quartile Range 0.00 2.19 1.20 0.89 
      
I T 100 9a 654 654 630 625 
 9b 620 610 592 595 
 9c 540 532 514 507 
 10a 510 498 480 495 
 10b 706 694 678 667 
 10c 624 624 606 598 
 Mean ± SD 609.00 ± 72.58 
602.00 ± 
74.07 
583.33 ± 
73.77 
581.17 ± 
67.36 
 Median (%) 100.00 98.45 95.76 95.70 
 Quartile Range 0.00 1.70 1.15 1.49 
      
A C 100 11a 540 542 528 525 
 11b 554 550 520 517 
 11c 480 470 458 460 
 12a 640 620 612 615 
 12b 660 660 638 630 
 12c 680 692 668 658 
 Mean ± SD 592.33 ± 589.00 ± 570.67 ± 567.50 ± 
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79.20 83.07 80.99 77.80 
 Median (%) 100.00 99.64 96.16 95.96 
 Median 0.00 2.45 2.36 1.30 
      
A C 200 13a 580 580 582 580 
 13b 590 590 590 595 
 13c 690 692 670 665 
 14a 590 570 546 545 
 14b 664 668 664 665 
 14c 560 560 542 545 
 Mean ± SD 612.33 ± 51.93 
610.00 ± 
55.66 
599.00 ± 
56.02 
599.17 ± 
54.63 
 Median (%) 100.00 100.00 98.55 98.66 
 Quartile Range 0.00 0.09 3.21 3.77 
      
AC 600 15a 687 682 668 652 
 15b 724 735 707 695 
 15c 584 560 537 541 
 16a 600 591 562 549 
 16b 625 618 604 595 
 16c 628 585 578 565 
 Mean ± SD 641.33 ± 53.59 
628.50 ± 
66.79 
609.33 ± 
65.52 
599.50 ± 
61.74 
 Median (%) 100.00 98.69 95.15 93.77 
 Quartile Range 0.00 3.38 5.20 3.70 
      
U P 150 17a 680 676 670 675 
 17b 614 606 590 600 
 17c 600 598 580 565 
 18a 562 576 558 560 
 18b 670 676 652 650 
 18c 548 536 526 530 
 Mean ± SD 612.33 ± 54.28 
611.33 ± 
55.67 
596.00 ± 
55.22 
596.67 ± 
56.18 
 Median (%) 100.00 99.54 96.99 97.37 
 Quartile Range 0.00 2.19 2.44 2.55 
      
U P 300 19a 624 612 588 580 
 19b 624 612 578 575 
 19c 590 570 558 560 
 20a 574 564 552 545 
 20b 628 624 598 600 
 20c 600 640 562 565 
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 Mean ± SD 606.67 ± 22.11 
603.67 ± 
30.26 
572.67 ± 
18.23 
570.83 ± 
18.82 
 Median (%) 100.00 98.17 94.40 94.54 
 Quartile Range 0.00 1.29 1.56 2.00 
      
UP 800 21a 690 647 604 595 
 22b 570 552 524 519 
 22c 588 587 582 579 
 23a 655 635 630 632 
 23b 575 567 553 549 
 23c 652 650 619 620 
 Mean ± SD 621.67 ± 50.36 
606.33 ± 
43.02 
585.33 ± 
40.73 
582.33 ± 
42.85 
 Median (%) 100.00 97.78 95.56 95.29 
 Quartile Range 0.00 2.85 4.25 5.44 
 
148 
 
Table 4.2.1 weight of feed (g) consumed in normal diet fed animals. 
 
 Animals 
per cage 
1st week 2nd week 3rd week 
Control 3 23.56 22.39 20.56 
 3 24.50 23.80 21.40 
 Mean 24.03 23.10 20.98 
 STD 0.6646804 0.9970206 0.59397 
     
Metformin 3 29.10 25.80 25.30 
 3 28.60 26.70 26.10 
 Mean 28.85 26.25 25.70 
 STD 0.3535534 0.6363961 0.565685 
     
Mixture 3 26.30 30.10 27.31 
 3 27.50 30.10 22.00 
 Mean 26.90 30.10 24.66 
 STD 0.8485281 0 3.754737 
     
 I T 50 3 22.83 23.17 26.35 
 3 23.83 30.94 28.00 
 Mean 23.33 27.06 27.18 
 STD 0.7071068 5.4942197 1.166726 
     
 I T 100 3 23.04 22.22 29.98 
 3 25.40 23.61 28.71 
 Mean 24.22 22.92 29.35 
 STD 1.668772 0.9828784 0.898026 
     
 A C 100 3 25.67 24.39 20.44 
 3 25.22 25.44 21.00 
 Mean 25.45 24.92 20.72 
 STD 0.3181981 0.7424621 0.39598 
     
 A C 200 3 25.21 22.83 30.60 
 3 23.90 22.67 21.67 
 Mean 24.56 22.75 26.14 
 STD 0.9263099 0.1131371 6.314464 
     
U P 150 3 29.60 31.40 30.30 
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 3 29.70 30.50 29.40 
 Mean 29.65 30.95 29.85 
 STD 0.0707107 0.6363961 0.636396 
     
U P 300 3 27.10 31.50 31.10 
 3 30.10 31.80 28.20 
 Mean 28.60 31.65 29.65 
 STD 2.1213203 0.212132 2.05061 
 
Table 4.2.2 weight of feed consumed in diet fed animals. 
 Animals 
per 
cage 
1st 
week 
2nd 
week 
3rd week 
     
Control 2 29.25 36.50 37.12 
 2 35.50 33.50 41.38 
 2 30.50 35.00 38.00 
 Mean 31.75 35.00 38.83 
 STD 2.70 1.22 1.84 
     
Metformin 2 28.70 22.30 30.80 
 2 26.70 30.10 31.50 
 2 33.00 22.40 23.40 
 Mean 29.47 24.93 28.57 
 STD 3.22 4.47 4.49 
     
Mixture 2 25.30 31.00 34.70 
 2 21.30 32.30 33.30 
 2 20.30 23.00 30.90 
 Mean 22.30 28.77 32.97 
 STD 2.65 5.04 1.92 
     
I T 50 2 31.30 30.70 25.00 
 2 40.60 25.00 27.60 
 2 39.30 29.50 30.40 
 Mean 37.07 28.40 27.67 
 STD 5.04 3.00 2.70 
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I T 100 2 39.00 25.30 27.00 
 2 28.10 28.30 37.00 
 2 28.00 22.00 24.20 
 Mean 31.70 25.20 29.40 
 STD 6.32 3.15 6.73 
     
A C 100 2 24.30 26.75 32.50 
 2 28.30 24.80 30.90 
 2 21.70 27.50 33.00 
 Mean 24.77 26.35 32.13 
 STD 3.32 1.39 1.10 
     
A C 200 2 26.30 22.80 41.00 
 2 27.30 27.80 39.00 
 2 24.30 30.00 38.70 
 Mean 25.97 26.87 39.57 
 STD 1.53 3.69 1.25 
     
AC 600 2 30.80 43.40 41.25 
 2 27.80 38.10 37.63 
 2 31.60 38.80 38.25 
 Mean 30.07 40.10 39.04 
 STD 2.00 2.88 1.94 
     
U P 150 2 22.00 25.00 30.90 
 2 24.30 23.00 43.00 
 2 28.00 29.80 43.80 
 Mean 24.77 25.93 39.23 
 STD 3.03 3.49 7.23 
     
U P 300 2 21.50 34.00 27.20 
 2 21.30 26.30 31.20 
 2 23.70 27.30 33.90 
 Mean 22.17 29.20 30.77 
 STD 1.33 4.19 3.37 
     
UP 800 2 38.50 38.87 38.25 
 2 32.50 39.50 36.00 
 2 27.75 38.00 35.88 
 Mean 32.92 38.79 36.71 
 STD 5.39 0.75 1.34 
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Table 4.3.1: oral glucose tolerance test results in normal diet fed group. 
 
 
Time 
(mins) 
 0 30 60 120 
Group 
mg/kg 
Animal code     
Control 15a 4.40 4.80 4.80 4.20 
 15b 4.20 5.60 5.50 5.10 
 15c 5.20 6.30 5.80 5.30 
 16a 4.50 6.10 6.10 5.20 
 16b 4.50 6.40 5.30 4.40 
 16c 3.80 4.60 3.40 4.20 
 Mean 
±SD 
4.43 ± 
0.46 
5.63 ± 
0.78 
5.15 ± 
0.97 
4.73 ± 
0.52 
      
Metformin 24a 4.70 5.60 4.30 4.10 
 24b 3.30 4.80 4.40 4.20 
 24c 4.50 5.40 4.70 3.30 
 20a 4.10 4.60 4.60 4.70 
 20b 3.80 5.80 5.40 4.10 
 20c 4.70 5.50 4.90 4.30 
 Mean 4.18 ± 
0.56 
5.28 ± 
0.48 
4.72 ± 
0.40 
4.12 ± 
0.46 
      
Mixed  21a 4.30 5.80 5.20 4.80 
 21b 4.60 4.40 3.40 2.90 
 21c 4.10 5.50 5.40 4.50 
 22a 4.60 5.90 5.60 4.40 
 22b 4.10 4.40 4.70 4.90 
 22c 4.00 4.70 4.30 4.70 
  4.28 ± 
0.26 
5.12 ± 
0.70 
4.77 ± 
0.82 
4.37 ± 
0.74 
      
I T 50    2a 3.70 5.70 4.50 4.20 
 2b 3.80 4.60 5.30 3.60 
 2c 3.10 3.30 3.90 3.20 
 1a 4.40 6.40 5.40 4.30 
 1b 3.80 6.50 5.80 4.20 
 1c 3.80 4.90 4.90 4.10 
      
I T 100 3a 4.80 5.50 5.80 5.40 
 3b 4.30 5.70 5.40 4.90 
 4a 3.90 7.30 4.20 4.10 
 4b 3.70 3.80 4.10 3.60 
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 4c 6.60 4.20 5.40 4.40 
  4.63 ± 
1.16 
5.35 ± 
1.38 
5.03 ± 
0.78 
4.48 ± 
0.70 
      
      
A C 100 13a 4.10 6.30 6.00 4.60 
 13b 3.80 8.20 6.00 5.00 
 13c 4.60 5.30 5.60 5.00 
 10a 4.70 6.10 5.90 5.00 
 10b 4.60 6.00 5.40 4.40 
 10c 4.80 6.00 5.00 5.20 
  4.43 ± 
0.39 
6.36 ± 
0.98 
5.65 ± 
0.40 
4.87 ± 
0.30 
      
A C 200 7a 3.60 4.50 4.20 3.20 
 7b 3.70 4.70 3.20 3.50 
 7c 3.80 4.40 3.80 4.70 
 9a 3.50 4.70 5.50 4.80 
 9b 4.30 4.70 4.60 4.70 
 9c 4.30 4.80 5.30 4.80 
 Mean 3.87 ± 
0.35 
4.63 ± 
0.15 
4.43 ± 
0.88 
4.28 ± 
0.73 
      
U P 150 18a 3.90 4.80 4.20 3.90 
 18b 3.90 4.60 3.90 4.60 
 18c 4.30 4.50 3.80 4.10 
 19a 4.40 4.70 4.90 4.60 
 19b 4.20 5.00 4.50 4.30 
 19c 4.10 5.50 4.60 4.20 
 Mean 4.13 ± 
0.21 
4.85 ± 
0.36 
4.32 ± 
0.43 
4.28 ± 
0.28 
      
U. P 300 6a 4.40 5.20 4.90 4.40 
 6b 3.40 4.20 4.20 3.70 
 6c 3.50 4.70 4.00 4.10 
 11a 3.40 4.20 4.60 3.80 
 11b 3.50 3.60 3.70 3.30 
 11c 3.20 4.40 3.30 3.40 
 Mean 3.57 ± 
0.42 
4.38 ± 
0.54 
4.12 ± 
0.58 
3.78 ± 
0.42 
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Table 4.3.2: oral glucose tolerance test results in high calorie diet fed 
group. 
 
Time 
(min) 
 0.00 30.00 60.00 120.00 
 Rat 
code 
    
Control 1a 4.10 4.30 5.30 4.80 
 1b 3.30 4.70 5.10 4.60 
 1c 3.40 5.20 5.30 4.30 
 2a 4.30 6.20 5.40 4.30 
 2b 4.00 4.30 4.70 4.40 
 2c 3.50 4.90 4.70 4.40 
  3.77 ± 
0.42 
4.93 ± 
0.71 
5.08 ± 
0.31 
4.47 ± 
0.20 
      
Metformin 3a 4.20 4.50 4.10 4.10 
 3b 3.60 5.70 5.20 3.70 
 3c 3.00 5.50 4.90 3.50 
 4a 3.40 5.00 5.20 4.40 
 4b 3.80 5.80 5.70 4.90 
 4c 3.60 5.30 5.02 4.12 
  3.60 ± 
0.40 
5.30 ± 
0.49 
5.02 ± 
0.53 
4.12 ± 
0.53 
      
Mixture 5a 3.30 4.10 4.40 3.90 
 5b 3.60 3.90 3.80 3.90 
 5c 4.10 4.70 5.00 4.80 
 6a 4.20 5.30 5.00 4.50 
 6b 4.40 3.60 4.00 3.90 
 6c 4.10 5.00 5.20 4.60 
  3.95 ± 
0.41 
4.43 ± 
0.67 
4.57 ± 
0.59 
4.27 ± 
0.41 
      
I T 50 7a 3.80 5.00 4.90 4.90 
 7b 4.70 5.80 4.90 4.90 
 7c 5.40 5.30 4.90 5.00 
 8a 4.20 3.90 4.20 4.90 
 8b 4.50 5.60 5.40 5.40 
 8c 4.30 5.90 5.60 5.10 
  4.48 ± 
0.54 
5.25 ± 
0.74 
4.98 ± 
0.49 
5.03 ± 
0.20 
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I T 100 9a 4.10 4.60 4.40 4.40 
 9b 3.80 4.80 4.10 4.40 
 9c 4.10 4.30 4.90 4.30 
 10a 5.00 5.70 5.00 5.00 
 10b 4.30 5.30 4.10 4.00 
 10c 4.40 5.10 5.50 5.10 
  4.28 ± 
0.41 
4.97 ± 
0.50 
4.67 ± 
0.56 
4.53 ± 
0.43 
      
A C 100 11a 4.20 3.40 3.60 4.30 
 11b 4.20 4.60 4.00 5.00 
 11c 3.60 4.90 4.60 4.40 
 12a 4.40 4.20 4.40 4.90 
 12b 4.10 4.30 4.60 3.90 
 12c 3.50 5.80 4.70 4.40 
  4.00 ± 
0.33 
4.53 ± 
0.62 
4.32 ± 
0.39 
4.48 ± 
0.37 
      
AC 200 13a 3.30 4.00 3.20 4.00 
 13b 3.90 5.20 5.40 4.70 
 13c 4.00 4.70 5.20 4.90 
 14a 3.70 5.30 5.10 5.00 
 14b 4.40 5.80 6.40 4.70 
 14c 4.80 4.70 5.50 4.40 
  4.02 ± 
0.53 
4.95 ± 
0.62 
5.13 ± 
1.05 
4.62 ± 
0.37 
      
AC 600 15a 3.20 4.70 4.30 4.00 
 15b 3.60 5.00 5.40 4.70 
 15c 3.80 5.20 4.20 4.60 
 16a 4.30 5.70 5.80 5.40 
 16b 3.90 5.40 6.50 5.40 
 16c 3.30 3.90 4.20 3.90 
  3.68 ± 
0.41 
4.98 ± 
1.41 
5.07 ± 
0.98 
4.67 ± 
0.65 
      
UP 150 17a 4.40 5.90 5.80 5.30 
 17b 3.60 4.80 5.10 4.60 
 17c 3.10 4.60 3.70 3.90 
 18a 4.20 5.30 5.00 4.40 
 18b 4.40 5.70 5.20 4.70 
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 18c 4.10 4.60 5.40 4.50 
  3.97 ± 
0.52 
5.15 ± 
0.57 
5.03 ± 
0.71 
4.57 ± 
0.45 
      
UP 300 19a 4.30 5.10 5.80 5.20 
 19b 3.60 5.90 5.50 4.70 
 19c 3.80 5.00 4.30 5.00 
 20a 4.20 5.70 5.30 4.80 
 20b 4.20 4.80 4.20 4.00 
 20c 3.40 5.00 4.10 4.30 
  3.92 ± 
0.37 
4.42 ± 
2.20 
4.87 ± 
0.75 
4.67 ± 
0.45 
      
U P 800 21a 4.10 6.00 5.50 5.30 
 22b 4.40 5.70 5.30 4.70 
 22c 3.60 5.10 6.10 4.30 
 23a 3.80 6.00 5.00 5.20 
 23b 4.30 5.80 5.20 4.30 
 23c 3.10 6.80 5.30 4.00 
  3.88 ± 
0.49 
5.90 ± 
0.55 
5.40 ± 
0.38 
4.63 ± 
0.53 
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Table 4.4.1 glucose concentration results in mmol/l for normal diet fed 
group. 
 
Week Week 1 2 3 4 
 (Rat code)     
Control 15a 7.86 7.86 6.29 11.01 
 15b 6.29 7.86 8.65 9.43 
 15c 7.07 10.22 5.50 9.43 
 16a 6.29 11.01 10.22 9.43 
 16b 7.86 5.50 10.22 7.07 
 16c 7.86 8.65 10.22 10.22 
 Mean ± SD 7.21 ± 
0.77 
8.52 ± 
1.95 
8.52 ± 
2.13 
9.43 ± 
1.32 
 Median (%) 100 117.5 130 136.67 
 Quartile 
Range 
0 44.44 54.5 20 
      
Metformin 24a 7.07 6.29 6.29 4.72 
 24b 4.72 8.65 6.29 5.50 
 24c 5.50 5.50 7.07 7.07 
 20a 6.29 8.65 6.29 4.72 
 20b 6.29 6.29 4.72 4.72 
 20c 5.50 6.29 6.29 3.93 
 Mean ± SD 5.90 ± 
0.88 
6.94 ± 
1.35 
6.16 ± 
0.77 
5.11 ± 
1.08 
 Median (%) 100 107.14 107.14 75 
 Quartile 
Range 
0 37.5 39.68 45.24 
      
Mixture 21a 6.29 4.72 6.29 6.29 
 21b 5.50 3.93 6.29 7.07 
 21c 6.29 7.07 6.29 8.65 
 22a 5.50 5.50 5.50 7.07 
 22b 5.50 5.50 3.93 9.43 
 22c 6.29 6.29 9.43 6.29 
 Mean ± SD 5.9 ± 
0.43 
5.50 ± 
1.11 
6.29 ± 
1.79 
7.47 ± 
1.29 
 Median (%) 100 100 100 128.57 
 Quartile 
Range 
0 25 14.9 37.5 
      
 I T 50 2a 5.50 7.07 5.50 8.65 
 2b 7.07 8.65 4.72 8.65 
 2c 6.29 10.22 6.29 10.22 
 1a 6.29 7.86 6.29 11.01 
 1b 7.07 5.50 5.50 11.01 
 1c 9.43 7.86 4.72 10.22 
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 Mean ± SD 8.38 ± 
1.35 
7.86  ± 
1.57 
5.50 ± 
0.70 
9.96 ± 
1.07 
 Median (%) 100 123.61 88.89 156.35 
 Quartile 
Range 
0 45.24 33.33 40.28 
      
I T 100 3a 7.07 3.93 7.86 7.86 
 3b 6.29 8.65 6.29 7.86 
 4a 5.50 4.72 6.29 7.07 
 4b 5.50 4.72 7.86 7.86 
 4c 4.72 4.72 6.29 7.07 
 Mean ± SD 5.82 ± 
0.90 
5.35 ± 
1.88 
6.92 ± 
0.86 
7.55 ± 
0.43 
 Median (%) 100 85.71 114.29 128.57 
 Quartile 
Range 
0 14.29 22.22 17.86 
      
A C 100 13a 7.86 4.72 4.72 7.86 
 13b 7.075 7.861 4.716 5.503 
 13c 7.075 4.716 4.716 10.219 
 10a 6.29 5.50 7.86 6.29 
 10b 7.07 7.86 4.72 10.22 
 10c 7.07 7.07 4.72 5.50 
 Mean ± SD 7.07 ± 
0.50 
6.29 ± 
1.49 
5.24 ± 
1.28 
7.60 ± 
2.20 
 Median (%) 100 93.75 66.67 100 
 Quartile 
Range 
0 44.44 0 66.67 
      
A C 200 7a 4.72 4.72 6.29 10.22 
 7b 7.07 8.65 3.93 10.22 
 7c 7.86 7.86 4.72 9.43 
 9a 6.29 6.29 3.93 11.79 
 9b 5.50 10.22 4.72 11.01 
 9c 7.07 5.50 6.29 10.22 
 Mean ± SD 7.6 ± 
1.16 
7.21 ±  
2.07 
4.98 ± 
1.07 
11.66 ± 
0.81 
 Median (%) 100 100 74.11 165.97 
 Quartile 
Range 
0 22.22 28.89 55.56 
      
U P 150  18a 7.07 6.29 7.07 7.86 
 18b 7.07 5.50 6.29 6.29 
 18c 5.50 5.50 5.50 7.86 
 19a 4.72 5.50 6.29 7.07 
 19b 5.50 4.72 6.29 8.65 
 19c 7.86 4.72 7.86 7.07 
 Mean ± SD 6.29 ± 
1.22 
5.37 ± 
0.59 
14.54 ± 
0.81 
7.73 ± 
0.82 
158 
 
 Median (%) 100 87.3 100 126.98 
 Quartile 
Range 
0 22.22 14.29 60 
      
U P 300 6a 5.50 4.72 5.50 8.65 
 6b 3.93 5.50 7.86 6.29 
 6c 6.29 5.50 7.07 5.50 
 11a 4.72 5.50 6.29 5.50 
 11b 3.93 7.86 5.50 6.29 
 11c 6.29 5.50 8.65 10.22 
 Mean ± SD 5.11 ± 
1.08 
5.76 ± 
1.07 
6.81 ± 
1.28 
7.07 ± 
1.93 
 Median (%) 100 102.08 135.42 158.57 
 Quartile 
Range 
0 52.5 27.5 43.33 
Table 4.4.2 glucose concentration in mmol/l results for high calorie diet 
fed group. 
  Baseline 1 2 3 
 Rat code     
Control 1a 8.41 9.18 7.65 9.18 
 1b 9.94 8.41 21.41 9.18 
 1c 9.94 9.18 13.00 10.71 
 2a 9.18 10.71 9.18 8.41 
 2b 9.18 8.41 9.18 10.71 
 2c 7.65 9.18 16.82 6.12 
 Mean±SD 9.05 ± 0.89 
9.18 ± 
0.84 
12.87 ± 
5.35 
9.05 ± 
1.75 
 Median (%) 100.00 100.70 115.39 100.00 
 Quartile Range 0.00 25.00 115.39 17.42 
      
Metformin 3a 13.00 8.41 9.94 7.65 
 3b 9.18 6.12 13.00 5.35 
 3c 9.18 6.88 12.24 8.41 
 4a 10.71 7.65 10.71 7.65 
 4b 6.88 9.94 6.88 9.18 
 4c 9.18 9.94 13.00 6.12 
 Mean±SD 9.96 ± 2.09 
8.38 ± 
1.62 
11.27 ± 
2.42 
7.60 ± 
1.46 
 Median (%) 100.00 73.21 116.67 69.05 
 Quartile Range 0.00 41.67 41.67 32.84 
      
Mixture 5a 4.72 8.65 9.43 7.07 
 5b 4.72 7.07 7.07 6.29 
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 5c 4.72 7.86 9.43 6.29 
 6a 3.93 9.43 9.43 6.29 
 6b 5.50 7.86 11.79 7.86 
 6c 6.29 9.43 7.86 9.43 
 Mean±SD 4.98 ± 0.81 
8.38 ±  
0.95 
9.17 ±  
1.62 
7.21 ±  
1.26 
 Median (%) 100.00 158.33 200.00 146.43 
 Quartile Range 0.00 33.33 64.29 16.67 
      
I T 50 7a 5.50 9.43 11.01 11.79 
 7b 7.86 5.50 5.50 7.07 
 7c 7.07 5.50 12.58 4.72 
 8a 4.72 7.86 13.36 6.29 
 8b 7.07 6.29 11.79 3.93 
 8c 6.29 7.07 7.07 5.50 
 Mean±SD 6.42 ± 1.16 
6.94 ± 
1.53 
10.22 ± 
3.18 
6.55 ± 
2.80 
 Median (%) 100.00 100.69 172.22 88.75 
 Quartile Range 0.00 88.89 87.50 66.67 
      
I T 100 9a 3.93 6.29 6.29 4.72 
 9b 6.29 5.50 9.43 14.15 
 9c 4.72 7.07 12.58 6.29 
 10a 7.07 6.29 11.79 5.50 
 10b 5.50 7.86 6.29 4.72 
 10c 7.86 7.86 11.01 14.15 
 Mean±SD 5.90 ± 1.47 
6.81 ± 
0.95 
9.56 ± 
2.74 
8.25 ± 
4.60 
 Median (%) 100.00 121.49 155.00 126.67 
 Quartile Range 0.00 61.11 26.67 94.29 
      
A C 100 11a 5.50 7.86 8.65 5.50 
 11b 5.50 8.65 10.22 6.29 
 11c 7.07 7.07 11.01 5.50 
 12a 5.50 8.65 7.07 7.07 
 12b 4.72 10.22 14.94 6.29 
 12c 7.07 8.65 21.22 5.50 
 Mean±SD 5.90 ± 0.96 
8.53 ± 
1.04 
12.18 ± 
5.16 
6.03 ± 
0.64 
 Median (%) 100.00 150.00 171.43 107.14 
 Median 0.00 34.92 144.44 50.79 
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AC 200 13a 5.50 7.86 7.86 8.65 
 13b 4.72 7.07 6.29 6.29 
 13c 5.50 9.43 6.29 18.08 
 14a 5.50 7.86 5.50 13.36 
 14b 5.50 10.22 4.72 12.58 
 14c 5.50 9.43 7.86 11.79 
 Mean±SD 5.37 ± 0.32 
8.62 ± 
1.22 
6.42 ± 
1.26 
11.79 ± 
4.07 
 Median (%) 100.00 160.71 123.81 221.43 
 Quartile Range 0.00 28.57 42.86 85.72 
      
AC 600 15a 7.07 7.07 13.36 7.07 
 15b 7.86 7.07 10.22 7.86 
 15c 7.86 8.65 11.01 8.65 
 16a 10.22 7.86 14.15 7.07 
 16b 12.58 8.65 11.79 5.50 
 16c 9.43 7.07 11.01 6.29 
 Mean±SD 9.17 ± 2.03 
7.73 ± 
0.77 
11.92 ± 
1.53 
7.07 ± 
1.11 
 Median (%) 100.00 83.46 134.23 84.62 
 Quartile Range 0.00 25.00 23.33 33.33 
      
UP 150 17a 7.07 6.29 8.65 3.93 
 17b 6.29 17.29 7.07 11.01 
 17c 5.50 7.07 14.15 5.50 
 18a 5.50 4.72 8.65 7.07 
 18b 5.50 8.65 13.36 6.29 
 18c 6.29 7.07 10.22 7.86 
 Mean±SD 6.03 ± 0.64 
8.52 ± 
4.49 
10.35 ± 
2.83 
6.94 ± 
2.41 
 Median (%) 100.00 120.40 159.82 119.64 
 Quartile Range 0.00 68.25 120.64 28.57 
      
UP 300 19a 6.29 8.65 14.94 7.86 
 19b 6.29 7.86 6.29 7.07 
 19c 5.50 5.50 6.29 5.50 
 20a 5.50 4.72 8.65 7.07 
 20b 6.29 6.29 7.86 5.50 
 20c 6.29 7.07 11.01 8.65 
 Mean±SD 6.06 ± 0.41 
6.68 ± 
1.47 
9.17 ± 
0.32 
6.94 ± 
1.26 
 Median (%) 100.00 106.25 141.07 118.75 
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 Quartile Range 0.00 25.00 60.17 28.57 
      
UP 800 21a 7.07 7.86 12.58 6.29 
 22b 8.65 11.79 13.36 9.43 
 22c 14.94 11.01 12.58 7.86 
 23a 11.01 9.43 13.36 7.86 
 23b 10.22 8.65 12.58 3.14 
 23c 10.22 8.65 15.72 6.29 
 Mean±SD 10.35 ± 2.65 
9.56 ± 
1.53 
13.36 ± 
1.22 
6.81 ± 
2.15 
 Median (%) 10.22 9.04 12.97 7.08 
 Quartile Range 2.36 2.36 0.79 1.57 
 
Table 4.5.1: calculated insulin concentration results in μu/ml for normal 
diet fed group. 
 
Week Week Baseline 1.00 3.00 4.00 
 (Rat code)     
Control 15a 6.51 8.02 11.27 12.21 
 15b 7.27 6.51 14.69 10.56 
 15c 4.00 7.27 8.02 9.74 
 16a 5.63 10.56 8.02 8.92 
 16b 5.63 12.21 9.77 13.04 
 16c 4.82 9.74 14.78 12.21 
 Mean ± SD 5.65 ± 1.17 9.05 ± 2.16 11.09 ± 3.08 11.12 ± 1.62
 Median (%) 100.00 184.69 184.00 209.47 
 Quartile Range 0.00 79.16 28.94 85.29 
      
Metformin 24a 5.51 0.75 0.75 1.00 
 24b 1.55 0.75 1.00 2.37 
 24c 4.01 1.00 4.00 4.00 
 20a 4.76 0.75 1.00 2.37 
 20b 5.51 0.75 4.76 6.45 
 20c 3.18 2.37 4.01 3.18 
 Mean ± SD 4.09  ±  
1.53 
1.06 ±  
0.65 
2.59 ±  
1.85 
3.23 ±  
1.87 
 Median (%) 100.00 20.40 75.41 99.88 
 Quartile 
Range 
0.00 34.71 78.71 67.33 
      
Mixture 21a 7.27 1.00 0.75 0.75 
 21b 5.63 1.00 3.26 0.75 
 21c 3.18 0.75 0.75 0.75 
 22a 7.27 6.51 1.50 0.75 
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 22b 4.82 1.50 0.75 0.75 
 22c 4.00 0.75 0.75 0.75 
 Mean ± SD 5.36  ±  
1.69 
1.92 ±  
2.27 
1.29 ± 
1.01 
0.75 ±  
0.00 
 Median (%) 100.00 21.20 19.73 14.47 
 Quartile 
Range 
0.00 13.43 8.00 8.46 
      
I T 50 2a 4.00 0.74 1.55 3.26 
 2b 2.37 1.55 2.37 0.74 
 2c 5.63 0.74 0.65 1.50 
 1a 4.00 0.74 0.74 0.69 
 1b 5.63 0.74 0.74 0.40 
 1c 3.26 1.55 0.74 3.18 
 Mean ± SD 4.15 ± 
1.30 
1.01 ± 
0.42 
1.13 ± 
0.69 
3.26 ± 
1.29 
 Median (%) 100.00 18.57 20.64 29.01 
 Quartile 
Range 
0.00 34.56 25.72 64.15 
      
I T 100 3a 5.63 2.00 0.75 3.18 
 3b 6.45 0.75 0.75 0.75 
 4a 4.00 0.75 0.75 0.75 
 4b 6.45 0.75 5.51 3.18 
 4c 1.45 0.44 0.74 1.13 
 Mean ± SD 4.80 ± 
2.12 
0.94 ± 
0.61 
1.70 ± 
2.13 
1.80 ± 
1.27 
 Median (%) 100.00 18.79 18.79 49.32 
 Quartile 
Range 
0.00 19.06 37.70 37.70 
      
A C 100 13a 7.27 1.55 0.75 5.63 
 13b 4.82 0.75 0.74 6.45 
 13c 3.26 1.00 1.50 0.75 
 10a 6.45 7.27 3.18 0.75 
 10b 4.82 1.55 0.75 0.75 
 10c 7.27 13.87 1.00 1.00 
 Mean ± SD 5.65 ± 
1.61 
4.33 ± 
5.27 
1.32 ± 
0.96 
2.56 ± 
2.71 
 Median (%) 100.00 31.53 15.51 19.34 
 Quartile 
Range 
0.00 91.33 32.37 63.68 
      
A C 200 7a 4.82 0.75 0.75 0.75 
 7b 7.27 7.27 1.00 0.75 
 7c 7.27 0.76 0.75 1.50 
 9a 4.00 0.75 0.75 1.00 
 9b 4.82 1.00 1.00 1.00 
 9c 9.74 2.37 0.75 11.27 
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 Mean ± SD 6.32 ±  
2.16 
2.15 ±  
2.59 
0.84 ±  
0.13 
2.71 ±  
4.20 
 Median (%) 100.00 19.80 14.69 20.74 
 Quartile 
Range 
0.00 8.71 8.46 9.45 
      
U P 150 18a 5.63 4.82 0.75 0.75 
 18b 4.00 0.75 0.75 0.75 
 18c 6.45 0.75 0.75 0.75 
 19a 5.63 0.74 0.74 0.75 
 19b 4.82 0.75 0.75 0.75 
 19c 3.18 0.75 4.00 0.75 
 Mean ± SD 4.95  ± 
0.25 
1.43 ± 
1.66 
1.29 ± 
1.33 
0.75 ± 
0.00 
 Median (%) 100.00 17.20 14.47 14.47 
 Quartile Range 0.00 10.43 5.61 5.45 
      
U P 300 6a 4.00 0.75 0.75 0.75 
 6b 5.63 1.50 1.50 0.75 
 6c 2.37 0.75 0.75 0.75 
 11a 4.82 0.75 3.18 0.75 
 11b 4.00 0.75 1.50 1.50 
 11c 2.37 0.75 4.51 0.75 
 Mean ± SD 3.86  ±  
1.31 
0.88  ± 
0.31 
2.03  ±  
1.50 
0.88 ± 
0.31 
 Median (%) 100.00 22.74 34.66 25.26 
 Quartile Range 0.00 12.94 39.41 16.13 
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Table 4.5.2: calculated insulin concentration results in μu/ml results for 
high calorie diet fed group. 
 
  Baseline 1 2 3 
 Rat code     
Control 1a 45.60 31.32 40.43 22.99 
 1b 37.95 19.67 76.28 40.43 
 1c 51.91 70.95 53.54 45.35 
 2a 38.78 81.49 97.54 115.91 
 2b 51.91 53.54 105.76 42.08 
 2c 45.60 35.46 37.08 44.55 
 Mean ± SD 45.29  ± 6.07 48.74 ± 24.14 68.44 ± 29.30 51.89 ± 32.43 
 Median (%) 100 90.45 152.06 92.53 
 Quartile Range 0 67.99 115.06 25.47 
      
Metformin 3a 29.65 8.10 0.74 25.49 
 3b 22.99 4.00 31.31 42.08 
 3c 44.55 26.32 17.18 11.39 
 4a 45.60 35.46 26.32 19.42 
 4b 37.95 25.49 18.26 7.27 
 4c 10.56 32.14 51.10 12.21 
 Mean ± SD 31.89 ± 13.59 21.92 ± 12.90 24.15 ± 16.81 19.64 ± 12.76 
 Median (%) 100 63.12 52.92 64.28 
 Quartile Range 0 50.47 97.61 90.06 
      
Mixture 5a 55.96 17.18 31.31 2.37 
 5b 44.55 16.35 23.83 3.18 
 5c 48.65 37.95 44.55 4.82 
 6a 46.20 46.20 0.74 4.82 
 6b 43.73 50.29 46.20 1.55 
 6c 0.74 56.76 40.43 7.27 
 Mean ± SD 39.97 ± 19.72 37.45 ± 17.15 31.18 ± 17.15 4.00 ± 2.07 
 Median (%) 100 89 73.77 8.52 
 Quartile Range 0 78.28 52.16 6.19 
      
I T 50 7a 44.55 6.45 0.74 0.74 
 7b 43.73 62.35 11.39 7.27 
 7c 24.66 27.99 13.04 3.18 
 8a 23.83 32.14 3.18 11.39 
 8b 36.29 26.32 18.01 2.37 
 8c 13.87 23.83 19.67 0.74 
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 Mean ± SD 31.16 ± 12.32 29.85 ± 18.23 11.01 ± 7.68 4.28 ± 4.22 
 Median (%) 100 124.2 37.83 9.72 
 Quartile Range 0 70.06 39.52 11.28 
      
I T 100 9a 25.49 19.67 4.00 0.74 
 9b 12.21 27.99 1.55 0.74 
 9c 12.21 26.32 1.55 5.63 
 10a 14.69 3.18 2.37 3.18 
 10b 3.18 33.80 0.74 0.74 
 10c 12.21 29.65 13.87 3.18 
 Mean ± SD 13.33 ± 7.16 23.44 ± 10.95 4.01 ± 4.95 2.37 ± 2.00 
 Median (%) 100 222.31 15.9 22.49 
 Quartile Range 0 165.58 10.6 19.98 
      
A C 100 11a 46.20 16.35 1.55 0.74 
 11b 40.43 11.39 0.74 0.74 
 11c 42.91 69.41 18.01 3.18 
 12a 27.99 25.49 21.33 3.18 
 12b 24.66 60.76 0.74 0.74 
 12c 31.31 59.97 16.35 1.55 
 Mean ± SD 35.58 ± 8.97 40.56 ± 25.62 9.79 ± 9.75 1.69 ± 1.20 
 Median (%) 100 126.42 22.27 3.99 
 Quartile Range 0 156.12 49.21 5.58 
      
AC 200 13a 46.20 8.10 0.74 0.74 
 13b 38.78 16.35 6.45 1.55 
 13c 42.08 24.66 21.33 5.63 
 14a 32.97 42.91 41.26 1.55 
 14b 45.38 61.56 37.95 0.74 
 14c 42.91 43.73 7.27 2.37 
 Mean ± SD 41.39 ± 4.89 32.88 ± 19.98 19.17 ± 17.25 2.10 ± 1.84 
 Median (%) 100 80.26 33.82 4.36 
 Quartile Range 0 87.96 67 3.88 
      
AC 600 15a 37.95 39.61 48.65 23.83 
 15b 18.84 7.27 30.48 30.48 
 15c 1.55 0.74 24.66 7.27 
 16a 38.78 3.18 23.83 11.39 
 16b 26.32 22.99 54.34 37.95 
 16c 50.29 19.67 47.02 44.55 
 Mean ± SD 28.96 ± 17.28 15.58 ± 14.78 38.16 ± 13.39 25.91 ± 14.67 
 Median (%) 100 43.43 144.99 116.39 
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 Quartile Range 0 48.75 112.96 99.01 
      
UP 150 17a 59.97 31.31 0.63 2.37 
 17b 16.35 47.02 6.45 1.55 
 17c 47.84 6.45 9.74 5.63 
 18a 38.78 0.88 18.84 0.74 
 18b 35.46 59.97 2.37 0.74 
 18c 36.29 67.85 11.39 4.00 
 Mean ± SD 39.12 ±  14.50 35.58 ±  27.70 8.24  ±  6.64 2.51 ±  1.96
 Median (%) 100 110.65 25.87 6.73 
 Quartile Range 0 173 32.79 8.93 
      
UP 300 19a 21.33 32.14 13.04 1.69 
 19b 21.33 43.73 20.50 0.74 
 19c 42.08 8.92 4.82 4.00 
 20a 32.97 45.38 27.99 0.88 
 20b 47.02 39.61 25.49 2.49 
 20c 37.95 13.87 8.92 0.88 
 Mean ± SD 33.78  ± 10.70 30.61  ± 15.65 16.79  ± 9.32 1.78  ± 1.28
 Median (%) 100 110.92 57.67 4.39 
 Quartile Range 0 114.15 6138 5.24 
      
U P 800 21a 21.33 7.27 30.48 13.87 
 22b 13.04 12.21 22.99 40.43 
 22c 55.96 44.55 0.74 55.96 
 23a 34.64 34.64 0.74 50.29 
 23b 11.39 51.10 23.83 8.10 
 23c 0.74 5.63 5.63 3.18 
 Mean ± SD 22.85  ± 19.77 25.90 ± 20.02 14.07  ± 13.20 28.64  ± 22.99 
 Median (%) 100 96.83 159.61 122.59 
 Quartile Range 0 369.07 207.06 238.98 
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Table 4.6.1 HOMA values in normal diet fed group 
 
Week  Baseline 1 2 3 
 (Rat code)     
Control 15a 2.28 2.80 3.15 5.97 
 15b 2.03 2.28 5.65 4.43 
 15c 1.26 3.30 1.96 4.08 
 16a 1.57 5.17 3.64 3.74 
 16b 1.97 2.99 4.44 4.10 
 16c 1.68 3.74 6.71 5.55 
 Mean ± SD 1.80 ±  0.37 3.38 ±  1.00 4.26 ±  1.72 4.65 ±  0.90
 Median (%) 100 187.1 228.33 150 
 Quartile Range 0 139.6 121.84 106.89 
      
Metformin 24a 1.73 0.21 0.21 0.21 
 24b 0.33 0.29 0.28 0.58 
 24c 0.98 0.25 1.26 1.26 
 20a 1.33 0.29 0.28 0.50 
 20b 1.54 0.21 1.00 1.35 
 20c 0.78 0.66 1.12 0.56 
 Mean ± SD 1.11  ± 0.52 0.61 ± 0.17 2.51  ± 0.48 0.77  ± 0.46
 Median (%) 100 23.36 75.36 79.62 
 Quartile Range 0 0.078 107.39 90.95 
      
Mixture 21a 2.03 0.21 0.21 0.21 
 21b 1.38 0.18 0.91 0.24 
 21c 0.89 0.24 0.21 0.29 
 22a 1.78 1.59 0.37 0.24 
 22b 1.18 0.37 0.13 0.32 
 22c 1.12 0.21 0.32 0.21 
 Mean ± SD 1.40 ± 0.43 0.47 ± 0.56 0.36 ± 0.28 0.25 ± 0.04 
 Median (%) 100 22.68 22.14 17.97 
 Quartile Range 0 18.51 17.05 13.47 
      
 I T 50 2a 0.98 0.23 0.38 1.25 
 2b 0.74 0.60 0.50 0.29 
 2c 1.57 0.34 0.18 0.68 
 1a 1.12 0.26 0.21 0.34 
 1b 1.77 0.18 0.18 0.19 
 1c 1.37 0.54 0.16 1.45 
 Mean ± SD 1.26 ± 0.38 0.36 ± 0.17 0.27 ± 0.14 0.70 ± 0.53 
 Median (%) 100 23.54 15 40 
 Quartile Range 0 18.37 27.5 75.62 
      
I T 100 3a 1.77 0.35 0.26 1.11 
 3b 1.80 0.29 0.21 0.26 
 4a 0.98 0.16 0.21 0.24 
 4b 1.58 0.16 1.93 1.11 
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 4c 0.30 0.09 0.21 0.35 
 Mean ± SD 1.29 ± 0.78 0.21 ± 0.09 0.56 ± 0.85 0.62 ± 0.67 
 Median (%) 100 16.11 21.47 62.77 
 Quartile Range 0 3.75 53.23 46.3 
      
A C 100 13a 2.54 0.33 0.16 1.97 
 13b 1.51 0.26 0.16 1.58 
 13c 1.02 0.21 0.32 0.34 
 10a 1.80 1.78 1.11 0.21 
 10b 1.51 0.54 0.16 0.34 
 10c 2.29 4.36 0.21 0.25 
 Mean ± SD 1.78 ± 0.56 1.25 ± 1.63 0.35 ± 0.38 0.78 ± 0.78 
 Median (%) 100 28.19 10.34 27.94 
 Quartile Range 0 81.28 21.58 65.3 
      
A C 200 7a 1.01 0.16 0.21 0.34 
 7b 2.29 2.80 0.18 0.34 
 7c 2.54 0.26 0.16 0.63 
 9a 1.12 0.21 0.13 0.53 
 9b 1.18 0.46 0.21 0.49 
 9c 3.06 0.58 0.21 5.12 
 Mean ± SD 1.87 ± 0.88 0.74 ± 1.02 0.18 ± 0.03 1.29 ± 1.90 
 Median (%) 100 18.85 9.7 37.74 
 Quartile Range 0 23.04 10.97 22.19 
      
U P 150  18a 1.77 1.35 0.24 0.26 
 18b 1.26 0.18 0.21 0.21 
 18c 1.58 0.18 0.18 0.26 
 19a 1.18 0.18 0.21 0.24 
 19b 1.18 0.16 0.21 0.29 
 19c 1.11 0.16 1.40 0.24 
 Mean ± SD 1.35 ± 0.27 0.37 ± 0.48 0.41 ± 0.49 0.25 ± 0.03 
 Median (%) 100 14.39 17.14 18.35 
 Quartile Range 0 2 4.5 4.61 
      
U P 300 6a 0.98 0.16 0.18 0.29 
 6b 0.98 0.37 0.53 0.21 
 6c 0.66 0.18 0.24 0.18 
 11a 1.01 0.18 0.89 0.18 
 11b 0.70 0.26 0.37 0.42 
 11c 0.66 0.18 1.73 0.34 
 Mean ± SD 0.83 ±  0.17 
0.22 ±  
0.08 
0.66 ±  
0.59 
0.27 ±  
0.10 
 Median (%) 100 27.77 53.00 28.65 
 QuartileRange 0 19.14 52.42 30.23 
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Table 4.6.2 HOMA values in high calorie diet fed group 
 
  Baseline 1 2 3 
 Rat code     
Control 1a 17.05 12.77 13.74 9.38 
 1b 16.77 7.35 72.60 16.49 
 1c 22.94 28.94 30.93 21.58 
 2a 15.82 38.78 39.79 43.34 
 2b 21.17 20.02 43.14 20.03 
 2c 15.50 14.47 27.73 12.12 
 Mean ± SD 18.21 ± 3.09 20.39 ± 11.61 37.99 ± 19.85 20.49 ± 12.11 
 Median 100 93.93 191.31 94.33 
 Quartile Range 0 51.23 116.68 20.17 
      
Metformin 3a 17.13 3.03 0.33 8.66 
 3b 9.38 1.09 18.09 10.01 
 3c 18.17 8.05 9.34 4.26 
 4a 21.70 12.05 12.53 6.60 
 4b 11.61 11.26 5.59 2.97 
 4c 4.31 14.20 29.53 3.32 
 Mean ± SD 13.72 ± 6.43 8.28 ± 5.25 12.57 ± 10.27 5.97 ± 2.93 
 Median 100 49.93 54.57 40.5 
 Quartile Range 0 79.35 144.79 51.52 
      
Mixture 5a 11.73 6.60 13.13 0.74 
 5b 9.34 5.14 7.49 0.89 
 5c 10.20 13.26 18.68 1.35 
 6a 8.07 19.37 0.31 1.35 
 6b 10.69 17.57 24.21 0.54 
 6c 0.21 23.80 14.13 3.05 
 Mean ± SD 8.37 ± 4.19 14.29 ± 7.36 12.99 ±8.37 1.32 ± 0.91 
 Median 100 147.14 147.53 11.36 
 Quartile Range 0 183.71 146.15 10.33 
      
I T 50 7a 10.90 2.71 0.36 0.39 
 7b 15.28 15.25 2.79 2.29 
 7c 7.75 6.84 7.29 0.67 
 8a 4.99 11.23 1.89 3.18 
 8b 11.41 7.36 9.44 0.41 
 8c 3.88 7.49 6.18 0.18 
 Mean ± SD 9.04 ± 4.31 8.48 ± 4.28 4.66 ± 3.51 1.19 ± 1.24 
 Median 100 94.03 60.28 6.66 
 Quartile Range 0 128.83 75.79 11.34 
      
I T 100 9a 4.45 5.50 1.12 0.16 
 9b 3.41 6.84 0.65 0.47 
 9c 2.56 8.28 0.87 1.57 
 10a 4.62 0.89 1.24 0.78 
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 10b 0.78 11.81 0.21 0.16 
 10c 4.27 10.36 6.78 2.00 
 Mean ± SD 3.35 ± 1.48 7.28 ± 3.88 1.81 ± 2.46 0.86 ± 0.77 
 Median 100 221.62 26.76 18.42 
 Quartile Range 0 199.78 8.84 33.233 
      
A C 100 11a 11.30 5.71 0.60 0.18 
 11b 9.89 4.38 0.34 0.21 
 11c 13.49 21.82 8.81 0.78 
 12a 6.84 9.80 6.71 1.00 
 12b 5.17 27.60 0.49 0.21 
 12c 9.85 23.05 15.42 0.38 
 Mean ± SD 9.42  ±  3.01 15.39 ±  9.95 5.39 ± 6.11 0.46 ±  0.35 
 Median 100 152.44 37.41 3.94 
 Quartile Range 0 183.51 92.71 3.67 
      
AC 200 13a 11.30 2.83 0.26 0.29 
 13b 8.13 5.14 1.80 0.43 
 13c 10.29 10.34 5.96 4.53 
 14a 8.06 14.99 10.09 0.92 
 14b 11.10 27.96 7.96 0.42 
 14c 10.49 18.33 2.54 1.24 
 Mean ± SD 9.90 ± 1.44 13.27 ± 9.25 4.77± 3.85 1.30 ± 1.62 
 Median 100 137.58 41.07 8.4 
 Quartile Range 0 122.65 49.5 8.09 
      
AC 600 15a 11.93 12.45 28.90 7.49 
 15b 6.58 2.29 13.84 10.65 
 15c 0.54 0.29 12.06 2.80 
 16a 17.61 1.11 14.98 3.58 
 16b 14.71 8.84 28.48 9.28 
 16c 21.08 6.18 23.00 12.45 
 Mean ± SD 12.08 ± 7.51 5.19 ± 4.82 20.21 ± 7.56 7.71 ± 3.87 
 Median 100 43.64 201.94 62.93 
 Quartile Range 0 30.72 133.07 102.72 
      
UP 150 17a 18.86 8.75 0.24 0.41 
 17b 4.57 36.14 2.03 0.76 
 17c 11.70 2.03 6.13 1.38 
 18a 9.48 0.18 7.24 0.23 
 18b 8.67 23.05 1.41 0.21 
 18c 10.14 21.34 5.17 1.40 
 Mean ± SD 10.57 ± 4.71 15.25 ± 13.99 3.70 ± 2.85 0.73 ± 0.55 
 Median 100 128.37 47.7 7.12 
 Quartile Range 0 248.37 36.14 11.38 
      
UP 300 19a 5.96 12.35 8.66 0.59 
 19b 5.96 15.28 5.73 0.23 
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 19c 10.29 2.18 1.35 0.98 
 20a 8.06 9.51 10.76 0.28 
 20b 13.14 11.07 8.91 0.61 
 20c 10.61 4.36 4.36 0.34 
 Mean ± SD 9.00  ±  2.85 9.13 ±  4.96 6.63  ±  3.47 0.50  ±  0.28 
 Median 100 101.1 81.94 4.28 
 Quartile Range 0 166.08 92.25 6.08 
      
U P 800 21a 6.71 2.54 17.04 3.88 
 22b 5.01 6.40 13.66 16.95 
 22c 37.15 21.79 0.42 19.55 
 23a 16.94 14.52 0.44 17.57 
 23b 5.17 19.64 13.32 1.13 
 23c 0.34 2.17 3.94 0.89 
 Mean ± SD 11.89 ± 13.54 11.18 ± 8.65 8.13 ± 7.39 9.99 ± 8.90 
 Median 100 106.72 255.76 80.744 
 Quartile Range 0 320.99 269.91 211.2 
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Table 4.7.1 calculated free fatty acid concentration results in mmol/l for 
normal diet fed group. 
 
Week Week Baseline 1 2 3 
 (Rat code)     
Control 15a 1.96 1.44 1.70 2.02 
 15b 0.87 1.70 1.84 1.79 
 15c 0.76 1.50 1.90 0.81 
 16a 1.39 2.10 1.80 1.39 
 16b 1.52 2.10 1.30 0.82 
 16c 0.87 1.50 1.25 0.79 
 Mean ± SD 1.23 ± 0.47 1.72 ± 0.30 1.63 ± 0.28 1.27 ± 0.55 
 Median (%) 100 161.75 136.59 101.53 
 Quartile Range 0 57.24 124.76 15.77 
      
Metformin 24a 1.15 0.32 0.62 1.12 
 24b 0.42 0.37 0.98 1.12 
 24c 1.13 0.29 0.71 0.86 
 20a 0.44 0.14 0.35 0.92 
 20b 1.40 0.14 0.98 0.69 
 20c 1.00 0.23 0.72 0.74 
 Mean ± SD 0.92 ± 0.40 0.25 ± 0.10 0.73 ± 0.24 0.91 ± 0.18 
 Median (%) 100 26.75 71 86.77 
 Quartile Range 0 8.82 16.71 135.1 
      
Mixture 21a 0.27 0.59 1.49 0.46 
 21b 0.46 1.84 0.78 0.96 
 21c 0.83 1.28 1.59 0.89 
 22a 0.69 0.93 1.05 1.55 
 22b 1.08 0.24 1.60 1.3 
 22c 0.96 0.31 0.85 1.8 
 Mean ± SD 0.72 ± 0.31 0.87 ± .62 1.23 ± 0.38 1.16 ± 0.49 
 Median (%) 100 144.5 160.87 178.94 
 Quartile Range 100 186.23 43.42 88.33 
      
I T 50 2a 1.52 1.03 0.86 0.91 
 2b 1.17 0.93 0.94 0.88 
 2c 0.47 2.40 1.77 1.58 
 1a 1.15 2.18 0.88 0.91 
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 1b 0.42 1.09 0.94 0.85 
 1c 1.28 1.50 1.20 1.5 
 Mean ± SD 1.00 ± 0.45 1.52 ±  0.63 1.10 ±  0.35 1.11 ± 0.34 
 Median (%) 100 153.38 87.05 98.16 
 Quartile Range 0 180.04 147.28 127.17 
      
I T 100 3a 1.13 1.13 0.89 0.92 
 3b 1.20 0.93 1.15 1.19 
 4a 1.33 1.40 1.96 1.84 
 4b 0.85 1.96 1.17 0.96 
 4c 1.00 1.00 1.43 1.45 
 Mean ± SD 1.10 ± 0.18 1.28 ± 0.42 1.32 ± 0.41 1.27 ± 0.38 
 Median (%) 100 100 137.65 112.94 
 Quartile Range 0 5.26 47.17 39.18 
      
A C 100 13a 1.20 2.03 1.55 1.61 
 13b 1.18 0.96 1.35 1.25 
 13c 1.01 1.01 0.91 1.1 
 10a 0.96 1.57 0.85 0.95 
 10b 1.15 1.35 1.37 1.2 
 10c 1.79 1.13 1.59 1.64 
 Mean ± SD 1.22 ± 0.30 1.34 ± 0.41 1.27 ± 0.32 1.29 ± 0.28 
 Median (%) 100 108.7 102.25 105.14 
 Quartile Range 0 82.19 30.3 9.95 
      
A C 200 7a 1.57 2.00 1.31 1.21 
 7b 1.01 1.03 1.04 0.95 
 7c 0.91 1.12 1.30 1.19 
 9a 0.81 0.93 1.91 1.55 
 9b 0.95 0.76 1.01 0.85 
 9c 2.00 1.32 1.40 1.25 
 Mean ± SD 1.21 ± 0.43 1.19 ± 0.40 1.33 ± 0.30 1.17 ± 0.25 
 Median (%) 100 108.4 104.64 91.77 
 Quartile Range 0 43.08 59.42 53.7 
      
U P 150 18a 0.47 0.90 0.91 1.06 
 18b 0.91 1.01 1.55 1.27 
 18c 0.36 1.17 1.65 1.49 
 19a 0.78 0.69 1.45 1.37 
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 19b 1.37 1.40 1.60 1.44 
 19c 0.64 0.91 0.29 0.32 
 Mean ± SD 0.76 ± 0.36 1.01 ± 0.25 1.24 ± 0.54 1.15 ± 0.44 
 Median (%) 100 126.59 178.11 157 
 Quartile Range 0 89.3 76.83 120.42 
      
U P 300 6a 0.96 0.28 0.86 0.31 
 6b 0.63 0.64 1.16 1.33 
 6c 0.26 0.56 1.06 0.42 
 11a 0.53 0.51 1.19 0.31 
 11b 0.56 0.29 1.34 0.86 
 11c 0.71 0.31 0.8 0.51 
 Mean ± SD 0.61 ± 0.23 0.43 ± 0.16 1.07 ± 0.21 0.62 ± 0.40 
 Median (%) 100 74 204.32 112.7 
 Quartile Range 0 57.93 126.61 103.05 
 
 
Table 4.7.2 calculated free fatty acid concentration results in mmol/l for 
special diet fed group. 
 
 
 Rat code Baseline 1 2 3 
Control 1a 1.39 1.30 1.87 1.12 
 1b 0.79 1.39 1.42 1.52 
 1c 0.85 1.15 1.50 2.08 
 2a 1.84 1.08 1.90 1.35 
 2b 0.83 2.01 2.50 2.31 
 2c 1.93 1.74 2.40 1.64 
 Mean ± SD 1.27 ± 0.52 1.45 ± 0.36 1.93 ± 0.45 1.67 ± 0.45 
 Median 100 114.41 155.5 138.68 
 Quartile Range 0 85.79 55.4 164.13 
      
Metformin 3a 1.07 1.30 1.40 1.35 
 3b 1.03 2.09 1.60 1.42 
 3c 1.62 1.67 1.40 1.31 
 4a 1.20 1.47 1.57 1.43 
 4b 1.70 0.91 1.12 1.05 
175 
 
 4c 1.84 2.07 1.50 1.32 
 Mean ± SD 1.41 ± 0.35 1.59 ± 0.46 1.43 ± 0.17 1.31 ± 0.14 
 Median 100 117 108.63 100.02 
 Quartile Range 0 19.41 49.32 54.43 
      
Mixture 5a 0.73 0.86 1.18 1.14 
 5b 0.93 1.33 1.12 0.43 
 5c 1.03 1.40 0.91 1.39 
 6a 0.78 1.20 1.33 1.89 
 6b 0.74 1.12 0.95 1.17 
 6c 1.08 1.12 0.56 1.07 
 Mean ± SD 0.88 ± 0.15 1.17 ± 0.19 1.01 ± 0.27 1.18 ± 0.47 
 Median 100 139.47 124.4 145.56 
 Quartile Range 0 33.54 73.29 59.03 
      
I T 50 7a 0.82 0.56 1.28 0.88 
 7b 0.81 1.13 1.37 1.06 
 7c 1.04 0.73 0.78 1.6 
 8a 0.56 0.80 1.00 0.56 
 8b 0.82 0.85 0.78 1.3 
 8c 0.71 0.88 0.96 1.76 
 Mean ± SD 0.79 ± 0.16 0.825 ± 0.19 1.03 ± 0.25 1.19 ± 0.45 
 Median 100 113.8 145.65 142.36 
 Quartile Range 0 69.31 74.01 51.22 
      
I T 100 9a 1.12 1.23 0.90 1.89 
 9b 1.92 1.31 1.50 0.76 
 9c 1.30 0.99 0.63 1.55 
 10a 1.23 1.89 1.25 0.81 
 10b 1.49 0.86 0.81 1.81 
 10c 1.45 1.40 1.40 0.81 
 Mean ± SD 1.42 ± 0.28 1.28 ± 0.36 1.08 ± 0.35 1.27 ± 0.54 
 Median 100 86.35 79.24 92.54 
 Quartile Range 0 41.59 42.19 65.61 
      
A C 100 11a 0.54 2.29 1.05 1.55 
 11b 0.78 0.98 0.78 0.86 
 11c 0.71 1.86 1.20 0.92 
 12a 0.91 0.86 0.79 0.81 
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 12b 0.49 1.01 0.88 1.11 
 12c 0.61 0.78 0.85 1.2 
 Mean ± SD 0.67 ± 0.16 1.30 ± 0.62 0.93 ± 0.17 1.08 ± 0.98 
 Median 100 167 154.18 163.15 
 Quartile Range 0 136.33 79.59 116.27 
      
AC 200 13a 0.73 0.98 0.76 0.98 
 13b 0.85 0.56 0.79 0.75 
 13c 1.04 0.66 1.05 0.86 
 14a 0.93 0.81 0.87 1.05 
 14b 1.28 0.91 0.95 0.56 
 14c 1.04 0.99 0.85 1.15 
 Mean ± SD 0.98 ± 0.19 0.82 ± 0.18 0.88 ± 0.11 0.89 ± 0.21 
 Median 100 79.09 93.25 99.41 
 Quartile Range 0 29.31 19.23 30.21 
      
AC 600 15a 1.20 1.89 1.70 1.27 
 15b 1.32 1.64 1.42 1.55 
 15c 1.28 2.31 2.40 1.86 
 16a 2.30 2.03 1.60 1.41 
 16b 1.20 2.40 2.33 1.34 
 16c 2.80 0.81 1.01 1.21 
 Mean ± SD 1.68 ± 0.69 1.85 ± 0.58 1.58 ± 0.86 1.44 ± 0.24 
 Median 100 140.87 124.62 108.75 
 Quartile Range 0 92.21 117.93 56.12 
      
UP 150 17a 1.00 0.95 0.78 0.44 
 17b 0.68 0.85 1.40 0.63 
 17c 1.32 1.50 0.88 1.1 
 18a 0.54 1.40 1.79 1.23 
 18b 0.71 1.12 1.27 1.33 
 18c 1.08 1.10 1.60 1.74 
 Mean ± SD 0.89 ± 0.29 1.15 ± 0.25 1.29 ± 0.40 1.08 ± 0.47 
 Median 100 119.32 163.51 126.88 
 Quartile Range 0 55.9 127.88 103.99 
      
UP 300 19a 0.81 1.60 0.54 1.14 
 19b 0.64 1.60 1.01 1.4 
 19c 0.88 1.20 0.66 1.01 
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 20a 0.82 1.63 0.86 1.12 
 20b 1.03 1.04 1.10 1.08 
 20c 0.79 1.10 0.88 0.41 
 Mean ± SD 0.83 ± 0.13 1.36 ± 0.28
0.84 ± 
0.21 
1.03 ± 
0.33 
 Median 100 168.39 105.84 125.68 
 Quartile Range 0 62.42 36.39 35.89 
      
U P 800 21a 0.59 1.23 1.48 1.41 
 22b 1.50 1.81 1.50 1.35 
 22c 1.44 2.16 1.44 1.52 
 23a 2.20 2.08 1.66 1.48 
 23b 1.22 1.13 1.13 1.15 
 23c 1.04 1.14 1.20 0.98 
 Mean ± SD 1.33 ± 0.54 1.59 ± 0.48
1.40 ± 
0.20 
1.32 ± 
0.21 
 Median 100 115.14 100 94.27 
 Quartile Range 0 55.55 22.76 15.56 
 
